Frederick R. Appelbaum

Q: What Schools Are Affiliated With Frederick R. Appelbaum

Frederick R. Appelbaum is affiliated with the following schools: University of Ulsan College of Medicine, University of Chicago, Case Western Reserve University, University of New Mexico, University of Washington

Frederick R. Appelbaum's AcademicInfluence.com Rankings

Medical

#525

World Rank

#711

Historical Rank

Hematology

World Rank

Historical Rank

medical Degrees

Frederick R. Appelbaum

Philosophy

#2254

World Rank

#3900

Historical Rank

Logic

#505

World Rank

#929

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Frederick R. Appelbaum's Degrees

Masters Medicine University of Washington

Why Is Frederick R. Appelbaum Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Frederick R. Appelbaum's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (2017) (3878)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. (2010) (3011)
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. (1986) (1400)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation (2017) (1382)
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. (2001) (1357)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (2006) (1300)
Reduced mortality after allogeneic hematopoietic-cell transplantation. (2010) (1297)
Age and acute myeloid leukemia. (2006) (1213)
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. (2000) (1134)
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. (2000) (1074)
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. (2001) (947)
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. (2001) (861)
Regimen-related toxicity in patients undergoing bone marrow transplantation. (1988) (850)
Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. (1997) (834)
All-trans-retinoic acid in acute promyelocytic leukemia. (1997) (801)
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. (2009) (773)
Chronic graft-versus-host disease and other late complications of bone marrow transplantation. (1991) (738)
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study (2000) (731)
Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. (1993) (695)
Factors that influence collection and engraftment of autologous peripheral-blood stem cells. (1995) (670)
Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. (1989) (667)
Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. (1996) (655)
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. (1998) (632)
Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. (1989) (629)
Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. (1998) (625)
Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. (1990) (592)
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. (1999) (572)
Marrow transplantation for the treatment of chronic myelogenous leukemia. (1986) (561)
A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. (1990) (542)
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. (2013) (536)
Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. (2011) (525)
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. (2015) (522)
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. (2014) (501)
Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. (1999) (497)
Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid Cancer (1991) (491)
Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. (2010) (472)
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. (2005) (449)
Cardiotoxicity associated with high-dose cyclophosphamide therapy. (1981) (446)
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. (2001) (439)
Haematopoietic cell transplantation as immunotherapy (2001) (435)
Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. (1989) (428)
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. (1996) (425)
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. (2002) (425)
Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. (1983) (422)
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence (2005) (422)
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. (1999) (414)
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. (2001) (413)
Hematopoietic-cell transplantation at 50. (2007) (412)
Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas (1995) (410)
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. (2003) (404)
A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. (1990) (402)
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. (1992) (399)
Acute Myeloid Leukemia in the Elderly : Assessment of Multidrug Resistance ( MDR 1 ) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy (1997) (397)
Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. (1997) (392)
Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. (2002) (389)
Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor (1995) (387)
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. (2001) (385)
Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. (1996) (381)
Thomas' hematopoietic cell transplantation (2003) (379)
Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. (2007) (368)
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. (2007) (366)
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (363)
Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. (1989) (362)
Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. (1987) (357)
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. (1997) (350)
Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. (1986) (350)
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. (2010) (349)
Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. (1995) (345)
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. (2011) (344)
Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. (1991) (340)
Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. (1996) (332)
Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. (1997) (326)
Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG‐CSF): an analysis of factors correlating with the tempo of engraftment after transplantation (1994) (324)
Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. (2014) (324)
The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. (1993) (323)
Transplantation of Allogeneic Peripheral Blood Stem Cells Mobilized by Recombinant Human Granulocyte Colony Stimulating Factor (1996) (320)
One million haemopoietic stem-cell transplants: a retrospective observational study. (2015) (316)
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. (2000) (315)
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. (2007) (314)
Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. (1989) (312)
Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. (1994) (311)
Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. (2013) (310)
Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts (1985) (309)
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? (2016) (307)
Ovarian function following marrow transplantation for aplastic anemia or leukemia. (1988) (307)
A disease risk index for patients undergoing allogeneic stem cell transplantation. (2012) (305)
Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. (2010) (303)
Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. (2007) (297)
Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. (1983) (295)
Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. (1998) (288)
Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. (1988) (279)
Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies. (1988) (278)
Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. (1985) (275)
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. (2011) (274)
Duration of immunosuppressive treatment for chronic graft-versus-host disease. (2004) (272)
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. (2002) (269)
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. (2019) (267)
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. (2012) (263)
Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. (2000) (260)
Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. (1987) (257)
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. (2004) (256)
Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome (1999) (254)
Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. (2002) (253)
Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation (1988) (251)
Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor (1993) (250)
Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. (1993) (249)
Unrelated donor marrow transplantation in children. (1995) (246)
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. (2007) (244)
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations (2006) (244)
Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. (1993) (240)
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. (2019) (239)
Growth and development following marrow transplantation for leukemia. (1986) (229)
Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases. (1995) (228)
Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. (2009) (226)
Samarium-153-EDTMP biodistribution and dosimetry estimation. (1993) (226)
Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. (1996) (223)
Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. (2010) (222)
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) (2002) (220)
Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. (2022) (218)
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. (2007) (217)
High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. (2003) (216)
Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia (2009) (216)
Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). (2001) (215)
Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. (2015) (214)
Monoclonal antibody-based therapies of leukemia and lymphoma. (1992) (214)
Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. (2008) (211)
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. (2002) (210)
Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. (2010) (209)
Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. (1997) (207)
The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. (1987) (207)
Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. (1993) (204)
Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. (1992) (201)
Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. (1993) (200)
Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. (2001) (198)
Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience (2000) (198)
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. (2006) (197)
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. (2003) (197)
Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. (2000) (195)
Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. (2010) (194)
HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. (1994) (193)
Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. (1993) (193)
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. (2002) (191)
Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma (1978) (189)
Cord-Blood Transplantation in Patients with Minimal Residual Disease. (2016) (189)
Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. (2010) (188)
Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. (2003) (188)
Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. (1985) (186)
A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031) (1998) (183)
SIROLIMUS (RAPAMYCIN) FOR THE TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE1 (2001) (182)
Marrow harvesting from normal donors. (1984) (182)
HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. (2003) (181)
A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). (1998) (178)
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. (2002) (178)
Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (2013) (177)
Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. (1994) (177)
Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. (1990) (176)
Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. (2007) (176)
Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor (2000) (176)
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. (2007) (176)
N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. (1990) (176)
THE USE OF RADIOLABELED ANTI‐CD33 ANTIBODY TO AUGMENT MARROW IRRADIATION PRIOR TO MARROW TRANSPLANTATION FOR ACUTE MYELOGENOUS LEUKEMIA (1992) (175)
Phase I-II trial of pentoxifylline for the prevention of transplant- related toxicities following bone marrow transplantation [published erratum appears in Blood 1992 Jun 15;79(12):3397] [see comments] (1991) (174)
Barriers to bone marrow transplantation for sickle cell anemia. (1996) (171)
Primary Treatment of Acquired Aplastic Anemia: Outcomes with Bone Marrow Transplantation and Immunosuppressive Therapy (1997) (170)
Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. (1989) (169)
Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. (1984) (169)
Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. (1996) (168)
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. (2008) (167)
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. (2017) (166)
Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients (1982) (164)
Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. (2000) (164)
Factors associated with graft rejection after HLA‐identical marrow transplantation for aplastic anaemia (1983) (163)
Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. (1997) (163)
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. (2012) (163)
A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. (1993) (161)
Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. (2016) (161)
ACUTE LETHAL CARDITIS CAUSED BY HIGH-DOSE COMBINATION CHEMOTHERAPY A Unique Clinical and Pathological Entity (1976) (159)
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. (2002) (158)
Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. (1987) (158)
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. (1999) (157)
Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation. (1990) (157)
Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. (1986) (155)
Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. (2012) (154)
Marrow transplantation for aplastic anemia. (1974) (152)
The current status of hematopoietic cell transplantation. (2003) (151)
Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. (2004) (150)
Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. (2001) (150)
Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. (1995) (149)
Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. (1998) (149)
Bone marrow transplantation in patients aged 45 years and older. (1986) (148)
Mixed Hematologic Chimerism After Allogeneic Marrow Transplantation for Severe Aplastic Anemia Is Associated With a Higher Risk of Graft Rejection and a Lessened Incidence of Acute Graft-Versus-Host Disease (1986) (148)
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. (2001) (147)
Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson (2014) (147)
Prolonged complete remission following high dose chemotherapy of burkitt's lymphoma in relapse (1978) (146)
The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. (2001) (145)
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. (2006) (144)
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. (2009) (144)
Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. (2012) (142)
Impact of patient weight on non-relapse mortality after marrow transplantation. (1995) (142)
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. (2007) (142)
Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. (2001) (141)
Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia (2016) (141)
Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. (1986) (140)
Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. (2003) (140)
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. (2012) (139)
Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. (2012) (138)
Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. (1982) (138)
Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. (1996) (137)
Allogeneic hematopoietic stem cell transplantation for myelofibrosis. (2003) (136)
Acute myeloid leukemia, version 2.2013 featured updates to the NCCN guidelines (2013) (135)
Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center (2014) (132)
Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. (1997) (131)
Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. (1997) (130)
A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. (1996) (129)
Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. (2010) (128)
Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. (2013) (127)
Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis of normal dogs and on hematopoietic recovery after otherwise lethal total body irradiation. (1989) (126)
Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. (1995) (126)
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. (2007) (126)
Late complications after marrow transplantation. (1984) (125)
Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse (1983) (125)
Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. (2009) (124)
Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. (1989) (124)
Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. (1990) (124)
A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. (2005) (123)
Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. (2005) (123)
Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. (2002) (123)
Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. (1991) (122)
US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. (2016) (122)
Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. (1996) (121)
Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. (1992) (120)
Thalidomide for treatment of patients with chronic graft-versus-host disease. (2000) (118)
High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. (1996) (118)
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. (2009) (117)
Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS‐related acute myeloid leukaemia (1996) (117)
Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR 1 / P-Glycoprotein , MRP 1 , and LRP in Acute Myeloid Leukemia . A Southwest Oncology Group Study (1999) (115)
Cord-Blood Transplantation in Patients with Minimal Residual Disease. (2016) (114)
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. (2021) (114)
Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. (1999) (113)
Late complications of allogeneic and autologous marrow transplantation. (1992) (113)
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. (2009) (112)
Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. (1987) (111)
Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. (1992) (111)
Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality (2017) (110)
Treatment of chronic myeloid leukemia by marrow transplantation [editorial; comment] [see comments] (1993) (110)
Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up (1988) (110)
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. (2007) (109)
Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. (2015) (109)
Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. (1997) (108)
Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. (1997) (108)
Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. (1993) (107)
Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. (1988) (107)
Gemtuzumab ozogamicin: time to resurrect? (2012) (106)
Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. (2011) (106)
Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. (1996) (106)
Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. (2011) (106)
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. (2005) (106)
Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. (1985) (106)
Result of attempted hematopoietic reconstitution using isologous, peripheral blood mononuclear cells: a case report. (1980) (105)
Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation (2002) (105)
Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study (2010) (105)
Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study (2002) (105)
Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403 (2014) (105)
Final adult height of patients who received hematopoietic cell transplantation in childhood. (2005) (104)
Effects of granulocyte colony-stimulating factor and stem cell factor, alone and in combination, on the mobilization of peripheral blood cells that engraft lethally irradiated dogs. (1994) (104)
Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. (1996) (104)
Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? (2013) (103)
Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. (2013) (103)
Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. (2005) (103)
Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. (1996) (103)
What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants ? (1990) (102)
Graft‐versus‐host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long‐term follow‐up of a controlled trial (1989) (102)
Implementing a Death with Dignity program at a comprehensive cancer center. (2013) (101)
A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. (1999) (101)
Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003–2007 Versus 2013–2017 Cohorts (2020) (101)
Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. (1978) (101)
The ligand for c-kit, stem cell factor, stimulates the circulation of cells that engraft lethally irradiated baboons. (1992) (100)
The detection of bone marrow involvement by lymphoma using magnetic resonance imaging. (1987) (100)
A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies (2006) (100)
Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials (1988) (100)
Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. (1982) (99)
Non‐myeloablative allografting from human leucocyte antigen‐identical sibling donors for treatment of acute myeloid leukaemia in first complete remission (2003) (98)
Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation (2003) (98)
The impact of obesity and disease on busulfan oral clearance in adults. (1999) (95)
Allogeneic marrow transplantation in the treatment of preleukemia. (1984) (95)
Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. (2001) (94)
Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation (1999) (94)
Second allogeneic transplantation after failure of first autologous transplantation. (2000) (93)
Allogeneic hematopoietic stem cell transplantation for acute leukemia. (1997) (93)
Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: changing impact of risk factors. (1986) (93)
Review of the use of marrow transplantation in the treatment of non-Hodgkin's lymphoma. (1983) (92)
In vivo synergy between recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in baboons enhanced circulation of progenitor cells. (1994) (92)
Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. (1995) (92)
Long-Term Follow-Up of a Randomized Trial of Two Irradiation Regimens for Patients Receiving Allogeneic Marrow Transplants During First Remission of Acute Myeloid Leukemia (1998) (91)
Association between pretransplant interferon-α and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase (1998) (90)
Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. (1990) (90)
Retrovirus-mediated gene transduction into long-term repopulating marrow cells of dogs. (1991) (90)
Bone marrow transplantation for refractory acute leukemia in 34 patients with identical twins. (1981) (90)
Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study. (2002) (89)
Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. (2004) (89)
Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia (2013) (89)
Effects of recombinant canine stem cell factor, a c-kit ligand, and recombinant granulocyte colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. (1993) (89)
Marrow transplantation for severe aplastic anemia. Long-term outcome in fifty "untransfused" patients. (1986) (89)
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. (1993) (89)
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. (2011) (89)
Interstitial pneumonitis following autologous bone marrow transplantation. (1986) (88)
Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma (2018) (88)
Recombinant human stem cell factor, a c-kit ligand, stimulates hematopoiesis in primates (1991) (88)
Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. (1987) (87)
End points to establish the efficacy of new agents in the treatment of acute leukemia. (2007) (87)
Prognostic factors and outcomes of severe gastrointestinal graft-vs.-host disease after allogeneic hematopoietic cell transplantation (2014) (87)
Treatment of preleukemic syndromes with marrow transplantation (1987) (87)
Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. (2003) (87)
The hemostatic imbalance of plasma-exchange transfusion. (1979) (87)
Comparison of Matched Unrelated and Matched Related Donor Myeloablative Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia in First Remission (2010) (87)
NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. (2014) (86)
The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. (2004) (86)
A c-kit ligand, recombinant human stem cell factor, mediates reversible expansion of multiple CD34+ colony-forming cell types in blood and marrow of baboons. (1992) (86)
Acute myeloid leukemia, version 2.2013. (2013) (86)
Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. (1991) (85)
Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. (2014) (85)
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. (2006) (85)
Gemtuzumab ozogamicin for acute myeloid leukemia. (2017) (84)
Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia. (2019) (84)
Treatment of aplastic anemia by bone marrow transplantation in identical twins. (1980) (84)
Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation. (1986) (83)
Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. (2003) (83)
Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia (2002) (83)
Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. (2001) (82)
Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. (1985) (82)
A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study. (1999) (81)
Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. (2005) (81)
Allogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia. (1988) (80)
The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer (1996) (79)
Clofarabine with high dose cytarabine and granulocyte colony‐stimulating factor (G‐CSF) priming for relapsed and refractory acute myeloid leukaemia (2011) (79)
Treatment of non-Hodgkin's lymphoma with marrow transplantation in identical twins. (1981) (79)
Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. (1999) (78)
Autologous marrow transplantation in patients with acute nonlymphocytic leukemia in first remission. (1985) (78)
Marrow transplantation for thalassemia. (1985) (78)
Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors (2014) (78)
Marrow transplantation for children in first remission of acute nonlymphoblastic leukemia: an update. (1985) (77)
Phenotyping of canine lymphoma with monoclonal antibodies directed at cell surface antigens: Classification, morphology, clinical presentation and response to chemotherapy (1984) (77)
Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. (2011) (77)
Acute myeloid leukemia clinical practice guidelines in oncology. (2006) (77)
Treatment of chronic myeloid leukemia by marrow transplantation. (1993) (77)
Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. (1985) (77)
Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). (2015) (76)
A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation (1993) (75)
HLA-identical marrow transplantation during accelerated-phase chronic myelogenous leukemia: analysis of survival and remission duration. (1988) (75)
Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. (1988) (75)
Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (2014) (75)
High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. (1994) (75)
Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation. (1991) (75)
Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts. (1989) (74)
Rapid engraftment by peripheral blood progenitor cells mobilized by recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in nonhuman primates (1995) (74)
Retrovirus-mediated gene transduction into canine peripheral blood repopulating cells. (1994) (74)
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. (2013) (73)
Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. (2005) (73)
Overview of the clinical relevance of autologous bone marrow transplantation. (1986) (73)
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia (2014) (73)
A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. (2000) (73)
Recombinant human stem cell factor, a c-kit ligand, stimulates hematopoiesis in primates. (1991) (73)
Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. (1997) (72)
Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease. (1985) (72)
Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. (1990) (72)
Transplantation of allogeneic peripheral blood stem cells (1996) (72)
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. (2010) (71)
Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration (2015) (71)
Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation. (1988) (71)
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. (2013) (71)
Unrelated donor or autologous marrow transplantation for treatment of acute leukemia. (1994) (70)
Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. (2001) (70)
Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients (1998) (70)
A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. (2005) (70)
Venocclusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation. (1987) (69)
Marrow transplant experience in children with acute lymphoblastic leukemia: an analysis of factors associated with survival, relapse, and graft-versus-host disease. (1985) (69)
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. (2011) (69)
Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction. (1994) (69)
Study of cell dose and storage time on engraftment of cryopreserved autologous bone marrow in a canine model. (1978) (68)
Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. (1997) (67)
Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. (1991) (67)
Immunosuppressive therapy of aplastic anemia: results of a prospective, randomized trial of antithymocyte globulin (ATG), methylprednisolone, and oxymetholone to ATG, very high-dose methylprednisolone, and oxymetholone. (1992) (67)
Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. (1998) (67)
Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. (2003) (67)
Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. (2001) (67)
Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis (1997) (66)
Personalized Dosing of Cyclophosphamide in the Total Body Irradiation–Cyclophosphamide Conditioning Regimen: A Phase II Trial in Patients With Hematologic Malignancy (2009) (66)
Long-Term Follow-up of a Randomized Study Comparing Cyclophosphamide and Total Body Irradiation With Busulfan and Cyclophosphamide for Patients Receiving Allogeneic Marrow Transplants During Chronic Phase of Chronic Myeloid Leukemia (1999) (66)
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. (2014) (66)
Therapy with mycophenolate mofetil for refractory acute and chronic graft-versus-host disease (2009) (66)
Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque. (1991) (65)
Treatment of hairy-cell leukemia with chemoradiotherapy and identical-twin bone-marrow transplantation. (1982) (65)
Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. (2004) (65)
Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. (1997) (65)
Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience (2004) (65)
Isolation of CD34+ cells from blood stem cell components using the Baxter Isolex system (1998) (65)
Consequences of Prior Alloimmunization during Granulocyte Transfusion (1977) (65)
Myasthenia gravis after allogeneic bone marrow transplantation (1986) (65)
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia (2010) (64)
Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. (2009) (64)
Changing trends in marrow transplantation for aplastic anemia. (1992) (63)
NCCN Clinical Practice Guidelines Acute myeloid leukemia. (2012) (63)
Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. (2002) (63)
Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience. (1994) (63)
A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study. (1993) (63)
Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications (2009) (62)
Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. (2004) (62)
Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. (2002) (61)
Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation (1998) (61)
Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. (2019) (61)
Marrow toxicity of fractionated vs. single dose total body irradiation is identical in a canine model. (1993) (61)
Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. (2004) (61)
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. (2005) (60)
Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. (2002) (60)
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype (2014) (60)
A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617. (2000) (59)
The Quality of Life of Adult Survivors of Childhood Hematopoietic Cell Transplant (2009) (59)
High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. (1988) (59)
Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance) (2013) (59)
Low relapse without excessive transplant-related mortality following myeloablative cord blood transplantation for acute leukemia in complete remission: a matched cohort analysis. (2009) (58)
Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia (2012) (58)
TREATMENT OF ACUTE GRAFT‐VERSUS‐HOST DISEASE WITH A NONMITOGENIC ANTI‐CD3 MONOCLONAL ANTIBODY (1992) (58)
Glutathione S-transferase theta 1 gene deletion and risk of acute myeloid leukemia. (2000) (58)
Syngeneic marrow transplantation in patients with multiple myeloma. (1996) (58)
Antibody-targeted therapy for myeloid leukemia. (1999) (57)
Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older (2001) (57)
Autologous bone marrow transplants: Different indications in Europe and North America (1989) (57)
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study (2019) (56)
Marrow transplantation following escalating doses of fractionated total body irradiation and cyclophosphamide--a phase I trial. (1992) (56)
Intensive chemoradiotherapy with autologous marrow transplantation for small cell carcinoma of the lung. (1983) (56)
Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. (1986) (56)
Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. (1996) (55)
An antibody that facilitates hematopoietic engraftment recognizes CD44. (1990) (55)
Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities (2000) (55)
Evaluation of a CD5-specific immunotoxin for treatment of acute graft- versus-host disease after allogeneic marrow transplantation (1996) (55)
FK‐506 AND METHOTREXATE PREVENT GRAFT‐VERSUS-HOST DISEASE IN DOGS GIVEN 9.2 Gy TOTAL BODY IRRADIATION AND MARROW GRAFTS FROM UNRELATED DOG LEUKOCYTE ANTIGEN‐NONIDENTICAL DONORS (1993) (55)
Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. (1992) (55)
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. (2013) (55)
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia (2014) (55)
Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia (2016) (55)
Long-Term Survival Analysis of the North American Intergroup Study C9011 Comparing Fludarabine (F) and Chlorambucil (C) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL). (2009) (55)
Phase I study of recombinant interleukin-1 beta in patients undergoing autologous bone marrow transplant for acute myelogenous leukemia. (1994) (54)
Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. (2012) (54)
Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL). (1997) (54)
Growth and development in children after bone marrow transplantation. (1988) (54)
Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. (1995) (54)
Twenty‐four‐color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia (2000) (54)
Marrow transplantation for Fanconi anemia with or without leukemic transformation: an update of the Seattle experience. (1992) (53)
Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. (2015) (53)
Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. (1989) (53)
Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer. (1995) (53)
Bone marrow transplantation for chronic myelogenous leukemia. (1995) (53)
Acute Myeloid Leukemia (2017) (52)
A PHASE I‐II STUDY EVALUATING THE MURINE ANTI‐IL-2 RECEPTOR ANTIBODY 2A3 FOR TREATMENT OF ACUTE GRAFT‐VERSUS-HOST DISEASE (1990) (52)
Single dose or fractionated total body irradiation and autologous marrow transplantation in dogs: effects of exposure rate, fraction size, and fractionation interval on acute and delayed toxicity. (1988) (52)
COMBINED IMMUNOSUPPRESSION WITH CYCLOSPORINE AND METHOTREXATE IN DOGS GIVEN BONE MARROW GRAFTS FROM DLA‐HAPLOIDENTICAL LITTERMATES (1984) (52)
Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation (1996) (52)
Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study (2001) (51)
Early mortality and overall survival of acute myeloid leukemia based on facility type (2017) (51)
Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. (2009) (51)
Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. (2014) (51)
Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. (1993) (50)
Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody. (1992) (49)
Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. (1996) (49)
The t(8;21) translocation is not consistently associated with high Bcl-2 expression in de novo acute myeloid leukemias of adults. (1998) (49)
Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. (1996) (49)
Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. (1994) (49)
Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. (1994) (48)
Prevention of transfusion-induced graft-versus-host disease in dogs by ultraviolet irradiation. (1989) (48)
SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML) (2016) (48)
Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report (2013) (47)
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. (2012) (47)
PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism. (2002) (47)
Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. (1996) (47)
PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. (2005) (47)
Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. (2008) (47)
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. (2014) (47)
The Problem of Thrombocytopenia after Hematopoietic Stem Cell Transplantation (1996) (47)
Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors. (1994) (46)
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. (2015) (46)
Ultraviolet irradiation of blood prevents transfusion-induced sensitization and marrow graft rejection in dogs (1986) (46)
Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia. (1996) (46)
Granulocyte Transfusion Therapy of Experimental Pseudomonas Septicemia: Study of Cell Dose and Collection Technique (1978) (46)
Lack of Predictive Value of Antileukocyte Antibody Screening in Granulocyte Transfusion Therapy (1979) (46)
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. (2011) (46)
Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. (2008) (46)
Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia (2003) (45)
Fanconi's anemia treated by allogeneic marrow transplantation. (1983) (45)
Thomas' hematopoietic cell transplantation : stem cell transplantation (2015) (45)
Economic Analysis of Granulocyte Colony Stimulating Factor as Adjunct Therapy for Older Patients with Acute Myelogenous Leukemia (AML): Estimates from a Southwest Oncology Group Clinical Trial (2001) (45)
Radiolabeled antibody therapy of lymphoma. (1993) (45)
Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG. (2011) (45)
Thrombocytopenia in dogs induced by granulocyte-macrophage colony-stimulating factor: increased destruction of circulating platelets. (1995) (44)
An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations (2017) (44)
Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen (2003) (44)
Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia [letter] (1994) (44)
Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. (1996) (44)
High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells. (1996) (43)
Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study (1997) (43)
Combined modality therapy of advanced non-Hodgkin's lymphoma: an analysis of remission duration and survival in 95 patients. (1983) (43)
A retrospective analysis of the long-term effect of splenectomy on late infections, graft-versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemia. (1995) (43)
Fractionated versus single-dose total body irradiation at low and high dose rates to condition canine littermates for DLA-identical marrow grafts. (1994) (43)
Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia. (2007) (43)
Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117 (2014) (42)
Cure of malignant lymphoma in dogs with peripheral blood stem cell transplantation. (1986) (42)
Rapid engraftment by peripheral blood progenitor cells mobilized by recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in nonhuman primates. (1995) (42)
Marrow transplantation for patients with acute lymphoblastic leukemia in first marrow remission. (1987) (42)
An update on allogeneic marrow transplantation for myelodysplastic syndrome. (1995) (42)
Treatment of aplastic anemia with antithymocyte globulin, high-dose corticosteroids, and androgens. (1987) (42)
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. (2007) (42)
Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. (2016) (42)
Engraftment in 86 with patients lymphoid malignancy after autologous marrow transplantation. (1989) (42)
Generation of HIV-1-specific CD8+ cell responses following allogeneic hematopoietic cell transplantation. (2008) (42)
Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia [letter] (1992) (41)
Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia. (1995) (41)
Acute myeloid leukemia. (2001) (41)
Hla-matched platelet transfusion therapy of severe aplastic anemia. (1978) (41)
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. (2011) (41)
Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantation. (1993) (41)
Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide. (1987) (41)
Functional dendritic cells are required for transfusion-induced sensitization in canine marrow graft recipients (1988) (40)
Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. (2006) (40)
High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma. (1989) (40)
A randomized trial of antihuman thymocyte globulin versus murine monoclonal antihuman T-cell antibodies as immunosuppressive therapy for aplastic anemia. (1985) (40)
Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission. (1989) (40)
Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. (2018) (39)
Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation. (1994) (39)
Comparison of morbidity and mortality after marrow transplantation from HLA-genotypically identical siblings and HLA-phenotypically identical unrelated donors. (1994) (39)
Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials (2013) (39)
Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. (1994) (39)
Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. (2010) (39)
New drug approvals in acute myeloid leukemia: what’s the best end point? (2015) (39)
Gamma-irradiation of pretransplant blood transfusions from unrelated donors prevents sensitization to minor histocompatibility antigens on dog leukocyte antigen-identical canine marrow grafts. (1994) (39)
Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents. (1998) (39)
What radiation dose for DLA-identical canine marrow grafts? [published erratum appears in Blood 1989 Feb;73(2):624] (1988) (38)
Treatment of children with acute promyelocytic leukemia: Results of the first North American intergroup trial INT0129 (2009) (38)
FLT 3 , RAS , and TP 53 mutations in elderly patients with acute myeloid leukemia (2001) (38)
Tumor suppressor gene alteration in adult acute lymphoblastic leukemia (ALL). Analysis of retinoblastoma (Rb) and p53 gene expression in lymphoblasts of patients with de novo, relapsed, or refractory ALL treated in Southwest Oncology Group studies. (1996) (38)
Ultraviolet irradiation of blood prevents transfusion-induced sensitization and marrow graft rejection in dogs. (1986) (38)
Effects of rhIL-11 on normal dogs and after sublethal radiation. (1995) (38)
Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission. (2013) (38)
High dose radiolabeled antibody therapy of lymphoma. (1990) (38)
Canine CD34: cloning of the cDNA and evaluation of an antiserum to recombinant protein. (1996) (38)
Long‐term survival after chemotherapy for acute myeloid leukemia (1997) (37)
Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. (2017) (37)
The pathogenesis of aplastic anemia. (1981) (37)
Trisomy 11: an association with stem/progenitor cell immunophenotype (1995) (36)
Marrow ablative and immunosuppressive effects of 131I-anti-CD45 antibody in congenic and H2-mismatched murine transplant models. (1999) (36)
Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation. (2015) (36)
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome (2021) (36)
A phase I / II trial of iodine-131 – tositumomab ( anti-CD 20 ) , etoposide , cyclophosphamide , and autologous stem cell transplantation for relapsed B-cell lymphomas (2000) (36)
Marrow transplantation for malignant plasma cell disorders: Summary of the Seattle experience * (1989) (36)
Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens (2001) (36)
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy (2014) (36)
A pilot study of low‐dose cyclosporin for graft‐versus‐host prophylaxis in marrow transplantation (1992) (36)
The influence of total dose, fractionation, dose rate, and distribution of total body irradiation on bone marrow transplantation. (1993) (36)
Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation. (1993) (36)
Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. (1998) (36)
Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia (2001) (36)
The use of radioimmunoconjugates in stem cell transplantation (2002) (36)
Allogeneic marrow transplantation following cyclophosphamide and escalating doses of hyperfractionated total body irradiation in patients with advanced lymphoid malignancies: a Phase I/II trial. (1995) (36)
Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine. (1985) (36)
Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial. (1995) (35)
The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011) (2013) (35)
Treatment of acute leukemia in adults with chemoradiotherapy and bone marrow transplantation (1985) (35)
High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer (1998) (35)
The Problem of Thrombocytopenia after Hematopoietic Stem Cell Transplantation (1996) (35)
What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? (1990) (35)
P73 mutations and expression in adult de novo acute myelogenous leukemia (1999) (34)
What radiation dose for DLA-identical canine marrow grafts? (1988) (34)
NCCN Practice Guidelines for Acute Myelogenous Leukemia. (2000) (34)
Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine? (1997) (34)
All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129. (2013) (34)
Hematopoietic cell transplantation with autologous cord blood in patients with severe aplastic anemia: An opportunity to revisit the controversy regarding cord blood banking for private use (2011) (34)
Management of the myelodysplastic syndromes. (1987) (34)
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial (2021) (34)
A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells. (2011) (34)
Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation (2000) (34)
Marrow transplantation for acute nonlymphocytic leukemia following therapy for Hodgkin's disease. (1987) (34)
Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms (2018) (34)
DLA-identical bone marrow grafts after low-dose total body irradiation: the effect of canine recombinant hematopoietic growth factors. (1994) (33)
High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer (1997) (33)
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia when a matched related donor is not available. (2008) (33)
Long-term follow-up of patients who received recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancy. (1991) (33)
High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. (1996) (33)
Specific marrow localization of an 131I-labeled anti-myeloid antibody in normal dogs: effects of a "cold" antibody pretreatment dose on marrow localization. (1989) (33)
SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia (2014) (33)
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. (2010) (32)
Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. (2000) (32)
Pursuing the goal of a donor for everyone in need. (2012) (32)
Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL). (1997) (32)
Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience. (2005) (32)
Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. (2020) (32)
Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. (2015) (32)
Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. (2008) (32)
Antibody-radionuclide conjugates as part of a myeloablative preparative regimen for marrow transplantation. (1989) (32)
Treatment of non‐Hodgkin's lymphoma with chemoradiotherapy and allogenic marrow transplantation (2007) (32)
Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. (2015) (31)
Granulocyte transfusion therapy of experimental Pseudomonas septicemia: study of cell dose and collection technique. (1978) (31)
Successful treatment of severe hemorrhagic cystitis with cystectomy following matched donor allogeneic hematopoietic cell transplantation (2000) (31)
Adhesion Of Acute Myeloid Leukemia Blasts To E-Selectin In The Vascular Niche Enhances Their Survival By Mechanisms Such As Wnt Activation (2013) (31)
Optimising the conditioning regimen for acute myeloid leukaemia. (2009) (31)
Bone marrow transplantation experience for children with aplastic anemia. (1986) (31)
Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease. (1987) (31)
Growth and development after bone marrow transplantation. (1989) (31)
Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study (2011) (31)
Marrow harvesting for autologous marrow transplantation. (1985) (31)
Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate 166Ho-EDTMP. (1992) (30)
Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3. (1991) (30)
PREVENTION OF TRANSFUSION‐INDUCED SENSITIZATION TO MINOR HISTOCOMPATIBILITY ANTIGENS ON DLA‐IDENTICAL CANINE MARROW GRAFTS BY GAMMA IRRADIATION OF MARROW DONOR BLOOD (1991) (30)
Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy. (1991) (30)
A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial (2010) (30)
Treatment of preleukemic syndromes with marrow transplantation. (1987) (30)
Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: a Southwest Oncology Group study (SWOG-8612). (1995) (30)
High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. (1997) (30)
Autologous bone marrow transplantation for acute lymphoblastic leukemia. (1993) (30)
A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. (1993) (30)
Prevention of graft-versus-host disease by immunosuppressive agents after transplantation of DLA-nonidentical canine marrow. (1986) (29)
Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG‐9500) (2007) (29)
Retrospective analysis of infectious disease in patients who received recombinant human granulocyte-macrophage colony-stimulating factor versus patients not receiving a cytokine who underwent autologous bone marrow transplantation for treatment of lymphoid cancer. (1998) (29)
Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up. (1988) (29)
Choosing the source of stem cells for allogeneic transplantation: no longer a peripheral issue. (1999) (29)
Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia (2010) (29)
Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies. (1995) (28)
Molecular cloning and in vivo evaluation of canine granulocyte-macrophage colony-stimulating factor. (1991) (28)
MARROW TRANSPLANT STUDIES IN DOGS WITH MALIGNANT LYMPHOMA (1985) (28)
Marrow transplantation in hepatitis‐associated aplastic anemia (1984) (28)
Engraftment of patients with lymphoid malignancies transplanted with autologous bone marrow, peripheral blood stem cells or both. (1995) (28)
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). (2020) (28)
Graft-Versus-Host Disease: A Surge of Developments (2007) (28)
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results (2021) (28)
Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia. (2008) (28)
Autologous marrow transplantation as consolidation therapy for canine lymphoma: efficacy and toxicity of various regimens of total body irradiation. (1985) (28)
Migration of transfused granulocytes in leukopenic dogs. (1977) (28)
Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia (2014) (28)
Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia (2013) (27)
Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation (2012) (27)
Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia (2012) (27)
FACILITATION OF ENGRAFTMENT OF DLA‐NONIDENTICAL MARROW BY TREATMENT OF RECIPIENTS WITH MONOCLONAL ANTIBODY DIRECTED AGAINST MARROW CELLS SURVIVING RADIATION (1987) (27)
A prospective randomized trial of HLA‐matched versus mismatched single‐donor platelet transfusions in cancer patients (1988) (27)
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. (2020) (27)
Effects of treatment regimens in patients allografted for acute and chronic myelogenous leukemia. (1991) (27)
Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia. (2013) (27)
Retrovirus-mediated transfer of the cDNA for human glucocerebrosidase into peripheral blood repopulating cells of patients with Gaucher's disease. (1997) (27)
Association of Distance from Transplantation Center and Place of Residence on Outcomes after Allogeneic Hematopoietic Cell Transplantation. (2016) (27)
The somatostatin analog octreotide in the management of the secretory diarrhea of the acute intestinal graft-versus-host disease in a patient after bone marrow transplantation. (1990) (26)
Impact of cranial irradiation added to intrathecal conditioning in hematopoietic cell transplantation in adult acute myeloid leukemia with central nervous system involvement. (2011) (26)
Lack of utility of chimerism studies obtained 2–3 months after myeloablative hematopoietic cell transplantation for ALL (2008) (26)
Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. (2001) (26)
Allogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006. (2011) (26)
Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation. (2001) (26)
Molecular diagnosis and clinical decisions in adult acute leukemia. (1999) (26)
Marrow transplantation for hematologic malignancies: a brief review of current status and future prospects. (1988) (26)
Increased AF1q gene expression in high‐risk myelodysplastic syndrome (2005) (26)
Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML). (2008) (26)
Hematopoietic cell transplantation in first complete remission versus early relapse. (2006) (25)
Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse. (1983) (25)
Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning (2005) (25)
Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning (2005) (25)
Functional dendritic cells are required for transfusion-induced sensitization in canine marrow graft recipients. (1988) (25)
Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. (2000) (25)
Biochemical characterization of a unique canine myeloid antigen. (1991) (25)
Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia (2015) (24)
Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts [letter] (1991) (24)
Marrow Transplantation for Thalassemia a (1985) (24)
Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes. (2008) (24)
Acute lymphoblastic leukaemia after bone marrow transplantation for aplastic anaemia (1986) (24)
Southwest Oncology Group Study S0910: A Phase 2 Trial of Clofarabine/ Cytarabine/ Epratuzumab for Relapsed/ Refractory Acute Lymphocytic Leukemia. (2009) (24)
Use of In Vitro Assays in Selection of Compatible Platelet Donors (1980) (24)
Multiparameter analysis of acute mixed lineage leukemia: correlation of a B/myeloid immunophenotype and immunoglobulin and T-cell receptor gene rearrangements with the presence of the Philadelphia chromosome translocation in acute leukemias with myeloid morphology. (1991) (24)
Targeted Busulfan and Cyclophosphamide as Compared to Busulfan and TBI as Preparative Regimens for Transplantation in Patients with Advanced MDS or Transformation to AML (2004) (24)
Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes (2003) (24)
Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial. (2016) (24)
Bone marrow transplantation in canine GM1 gangliosidosis (1990) (23)
Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective, randomized trial (1997) (23)
Unrelated and HLA‐Nonidentical Related Donor Marrow Transplantation forThalassemia and Leukemia: A Combined Report from the Seattle Marrow Transplant Team and the International Bone Marrow Transplant Registry a (1998) (23)
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. (2014) (23)
Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) experience. (1994) (23)
Failure of autologous marrow reconstitution after cytolytic treatment of marrow with anti-Ia monoclonal antibody. (1985) (23)
Prediction of CR following a second course of ‘7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course (2016) (23)
Chronic myelogenous leukemia: Prolonged survival with spontaneous decline in the frequency of Ph1‐positive cells and subsequent development of mixed Ph1‐positive and Ph1‐negative blast crisis (1983) (23)
Responsibility for costs associated with clinical trials. (2014) (22)
Allogeneic marrow transplantation and the use of hematopoietic growth factors (1995) (22)
Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models (2016) (22)
Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia (2015) (22)
Treatment of normal donors with recombinant growth factors for transplantation of allogeneic blood stem cells. (1996) (22)
131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). (2005) (22)
Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation (2020) (22)
Marrow transplantation for severe aplastic anemia and thalassemia major. (1991) (22)
Allogeneic and syngeneic marrow transplantation following high dose dimethylbusulfan, cyclophosphamide and total body irradiation. (1987) (22)
A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia. (2000) (22)
What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)? (2008) (22)
Prognostic significance of acquired copy‐neutral loss of heterozygosity in acute myeloid leukemia (2015) (21)
The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations (2017) (21)
Stimulation of canine hematopoiesis by recombinant human granulocyte-macrophage colony-stimulating factor. (1989) (21)
Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma. (2014) (21)
Structural and functional Alterations of FLT 3 in Acute Myeloid Leukemia (2009) (21)
Success of allogeneic marrow transplantation for children with severe aplastic anaemia (2012) (21)
Phase I study of recombinant human interleukin-1β (rhIL-1β) in patients with bone marrow failure (1994) (21)
Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. (1999) (20)
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR (2021) (20)
Hemopoietic reconstitution following autologous bone marrow and peripheral blood mononuclear cell infusions. (1979) (20)
Late failure of autologous marrow grafts in lethally irradiated dogs given anti-class II monoclonal antibody. (1991) (20)
Modified total body irradiation as a planned second high-dose therapy with stem cell infusion for patients with bone-based malignancies. (2006) (20)
Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia (2013) (20)
Effect of recombinant canine granulocyte-macrophage colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. (1994) (20)
Hematopoietic cell transplantation for non-Hodgkin's lymphoma: yesterday, today, and tomorrow. (2008) (20)
Who should be transplanted for AML? (2001) (19)
Phenotypic characterization of canine lymphoma, using monoclonal antibodies and a microlymphocytotoxicity assay. (1988) (19)
Conditioning Intensity and Peri-Transplant Flow Cytometric MRD Dynamics in Adult AML. (2022) (19)
The clinical use of hematopoietic growth factors. (1989) (19)
Unfavorable, complex, and monosomal karyotypes: the most challenging forms of acute myeloid leukemia. (2012) (19)
Decreased IRF8 expression found in aging hematopoietic progenitor/stem cells (2009) (19)
Alternative donor transplantation for adults with acute leukemia. (2014) (19)
Carboplatin infusion in relapsed and refractory acute myeloid leukemia--a Southwest Oncology Group trial. (1995) (19)
Impact of Pre-Transplant Measurable Residual Disease on Outcome of Allogeneic Hematopoietic Cell Transplantation in Adult Monosomal Karyotype AML (2020) (18)
Hematopoietic cell transplantation from unrelated donors for treatment of patients with acute myeloid leukemia in first complete remission. (2007) (18)
Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. (1996) (18)
Bone marrow transplantation for malignant lymphoma. (1987) (18)
Consequences of cryopreserving first remission autologous marrow for use after relapse in patients with acute myeloid leukemia. (1993) (18)
L-leucyl-L-leucine methyl ester treatment of canine marrow and peripheral blood cells. Inhibition of proliferative responses with maintenance of the capacity for autologous marrow engraftment. (1988) (18)
Radiolabeled antibody therapy of lymphomas. (1995) (18)
Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. (1994) (18)
Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model. (2005) (18)
Blood and marrow transplant clinical trials network state of the Science Symposium 2014. (2015) (18)
Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. (2020) (18)
Dose rate-dependent marrow toxicity of TBI in dogs and marrow sparing effect at high dose rate by dose fractionation. (1999) (18)
Recurrence of aplastic anemia following cyclophosphamide and syngeneic bone marrow transplantation: evidence for two mechanisms of graft failure (1985) (17)
Effect of recombinant canine granulocyte-macrophage colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation (1994) (17)
Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation. (1997) (17)
G‐CSF Priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm (2015) (17)
Marrow transplantation for hepatitis-associated aplastic anemia: a follow-up of long-term survivors. (1996) (17)
The Prognostic Significance of IRF8 Transcripts in Adult Patients with Acute Myeloid Leukemia (2013) (17)
Epitope Specificity of CD44 for Monoclonal Antibody–Dependent Facilitation of Marrow Engraftment in a Canine Model (1998) (17)
Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis. (2011) (17)
Dose rate-dependent sparing of the gastrointestinal tract by fractionated total body irradiation in dogs given marrow autografts. (1998) (17)
Selection of patients with Hodgkin's disease and non-Hodgkin's lymphoma for bone marrow transplantation. (1986) (17)
Hemopoietic reconstitution following autologous bone marrow and peripheral blood mononuclear cell infusions. (1979) (17)
A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation. (2011) (17)
Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation. (1998) (17)
Generic immunosuppressants in hematopoietic cell transplantation. (2011) (17)
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). (2018) (17)
Value of routine ‘day 14’ marrow exam in newly diagnosed AML (2014) (17)
The use of colony stimulating factors in marrow transplantation (1993) (17)
Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia (2014) (16)
Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study. (2009) (16)
Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI (2016) (16)
Perspectives on the future of chronic myeloid leukemia treatment. (2001) (16)
Cyclosporine (CSP)or CSP plus methylprednisolone for graft-versus-host disease prophylaxis in patients with high-risk lymphohemopoietic malignancies: long-term follow-up of a randomized trial. (2000) (16)
Accelerated hemopoietic recovery following the infusion of cryopreserved autologous bone marrow in humans. (1979) (16)
Lithium and acute monocytic leukemia. (1980) (16)
Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia [letter] (1992) (16)
Thalidomide for treatment of patients with chronic graft-versus-host disease (2000) (16)
Hematopoietic Cell Transplantation after Solid Organ Transplantation. (2015) (16)
Simultaneous infusion of high-dose cytosine arabinoside with cyclophosphamide followed by total body irradiation and marrow infusion for the treatment of patients with advanced hematological malignancy. (1988) (16)
Transplantation of allogeneic CD34+ peripheral blood stem cells (PBSC) in patients with advanced hematologic malignancy. (1996) (16)
Use of granulocyte colony-stimulating factor following hematopoietic cell transplantation: does haste make waste? (2004) (16)
Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. (1992) (16)
Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17) (2012) (16)
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report (2020) (16)
Sensitivity of renal cell cancer to nonmyeloablative allogeneic hematopoietic cell transplantations: unusual or unusually important? (2002) (16)
Hemopoietic stem cell transplantation for myelodysplastic syndrome (2000) (16)
Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. (2008) (16)
Autologous bone marrow transplantation in adults with non‐Hodgkin's lymphoma: A southwest oncology group study (1994) (15)
Rescue from anti-MHC class II antibody-mediated marrow graft failure by c-kit ligand. (1994) (15)
Cyclic neutropenia as a premalignant manifestation of acute lymphoblastic leukemia (1986) (15)
A Phase II Trial of 90Y-Ibritumomab Tiuxetan-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma (NHL). (2006) (15)
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). (2015) (15)
Curative Therapy of Advanced Essential Thrombocythemia or Polycythemia Vera by Hemopoietic Stem Cell Transplantation (2002) (15)
A Phase II Trial of 90Y-Ibritumomab Tiuxetan-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma (NHL). (2006) (15)
Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #110 (2014) (15)
Post therapy imaging in high dose I-131 radioimmunotherapy patients. (1994) (15)
Who should be transplanted for AML (2001) (15)
N-ras Mutations in Acute Myelogenous Leukemia: A Review of the Current Literature and an update of the Southwest Oncology Group Experience (1992) (15)
Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia (2016) (15)
Impact of allogeneic hematopoietic cell transplantation on the outcome of older patients with acute myeloid leukemia. (2017) (15)
Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults 60 Years Old With Relapsed or Refractory B-Cell Lymphoma (2007) (15)
Declining Rates of Treatment-Related Mortality in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Given “Intensive” Induction Regimens: A Report From the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA) (2012) (15)
Radiolabeled monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. (1991) (15)
Quantitative Effect of Age In Predicting Empirically-Defined Treatment-Related Mortality and Resistance In Newly Diagnosed AML: Case Against Age Alone as Primary Determinant of Treatment Assignment (2010) (15)
Chronic Graft-versus-Host Disease: Pathogenesis, Diagnosis, Treatment, and Prognostic Factors (1988) (15)
A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102 (2020) (14)
The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials (2013) (14)
Deletion of immunosuppressive prophylaxis after marrow transplantation increases hyperacute graft-versus-host disease but does not influence chronic graft-versus-host disease or relapse in patients with advanced leukemia (1989) (14)
Stimulation of hematopoiesis in vivo by stem cell factor. (1994) (14)
NCCN preliminary non-Hodgkin's lymphoma practice guidelines. (1997) (14)
Phase II Studies of Different Schedules and Doses of the Farnesyl Transferase Inhibitor Tipifarnib (R115777, Zarnestra, NSC-702818) for Patients of Age 70 or Older with Previously Untreated Acute Myeloid Leukemia (AML): A North American Intergroup Study (S0432). (2007) (14)
Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. (1992) (14)
Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60 (2015) (14)
Epitope specificity of CD44 for monoclonal antibody-dependent facilitation of marrow engraftment in a canine model. (1998) (14)
Wintrobe's clinical hematology: Fourteenth edition (2018) (14)
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. (2021) (14)
Recombinant human granulocyte colony-stimulating factor accelerates hematopoietic recovery after DLA-identical littermate marrow transplants in dogs. (1990) (14)
Biodistribution and dosimetry following infusion of antibodies labeled with large amounts of 131I. (1991) (14)
Methods for assessment of graft-versus-host disease. (1998) (13)
Long-term follow-up of 103 patients who received recombinant human granulocyte-macrophage colony-stimulating factor after unrelated donor bone marrow transplantation [letter] (1993) (13)
Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission: Results From North American Leukemia Intergroup Trial C9710 (2011) (13)
Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia (2020) (13)
ENGRAFTMENT OF DLA‐NONIDENTICAL BONE MARROW FACILITATED BY RECIPIENT TREATMENT WITH ANTI‐CLASS II MONOCLONAL ANTIBODY AND METHOTREXATE (1987) (13)
Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study (2017) (13)
High-dose radioimmunotherapy of B cell lymphomas. (1990) (13)
Retrovirus-Mediated Gene Transduction Into Canine Peripheral Blood Repopulating Cells (1994) (13)
American Society for Blood and Marrow Transplantation guidelines for training. (2001) (13)
Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials (2017) (13)
Autologous Marrow Transplantation for Malignant Lymphoma (1986) (13)
Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources. (2019) (13)
Allogeneic stem cell transplantation for relapsed and refractory acute myeloid leukemia patients with 11q23 abnormalities. (2000) (13)
Use of iodine-131-labeled anti-immune response-associated monoclonal antibody as preparative regimen prior to bone marrow transplantation: initial dosimetry. (1987) (12)
Risk Factors for the Development of Acute and National Institute of Health (NIH) Chronic Graft-Versus-Host Disease (GVHD). (2009) (12)
Is there a best transplant conditioning regimen for acute myeloid leukemia (2000) (12)
Stem-cell transplantation for myelofibrosis. (2001) (12)
Benchmarks in clinical productivity: a national comprehensive cancer network survey. (2007) (12)
Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy. (1996) (12)
Study on contribution of genetically marked peripheral blood repopulating cells to hematopoietic reconstitution after transplantation. (1994) (12)
Three-color versus four-color multiparameter cell cycle analyses of primary acute myeloid leukemia samples. (2000) (12)
Marrow transplantation in patients with acute myeloid leukemia. (1992) (12)
Gamma radiation of blood products prevents rejection of subsequent DLA-identical marrow grafts. Tolerance versus abrogation of sensitization to non-DLA antigens. (1996) (12)
Frequency and Clinical Signiﬁcance of the Expression of the Multidrug Resistance Proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study (1999) (12)
PHARMACOLOGIC, TOXICOLOGIC, AND MARROW TRANSPLANTATION STUDIES IN DOGS GIVEN SUCCINYL ACETONE (1992) (12)
Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype (2011) (12)
Allogeneic hematopoietic cell transplantation after conditioning with 131 I – anti-CD 45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome (2009) (12)
Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia (2019) (12)
Preparative regimens and ageism. (2011) (12)
Reduced Incidence of Acute and Chronic Graft-versus-Host Disease (GvHD) without Increased Relapse in Patients with High-Risk Myeloid Disorders Given Thymoglobulin (THY) as Part of the Transplant Conditioning Regimen: A Dose-Finding Study. (2004) (11)
Preliminary Results from the North American Acute Promyelocytic Leukemia (APL) Study C9710. (2006) (11)
The use of radiolabeled antibodies in bone marrow transplantation for hematologic malignancies. (1997) (11)
Toxicity trial of prophylactic 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine (ganciclovir) after marrow transplantation in dogs (1988) (11)
Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902 (2015) (11)
ATRA, Arsenic Trioxide (ATO), and Gemtuzumab Ozogamicin (GO) Is Safe and Highly Effective in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia (APL): Final Results of the SWOG/Alliance/ECOG S0535 Trial (2016) (11)
Global Hematopoietic Stem Cell Transplantation (HSCT) At One Million: An Achievement Of Pioneers and Foreseeable Challenges For The Next Decade. A Report From The Worldwide Network For Blood and Marrow Transplantation (WBMT) (2013) (11)
Molecular diagnosis and clinical decisions in adult acute leukemia. (1999) (11)
STUDIES OF THE USE OF L‐LEUCYL‐L‐LEUCINE METHYL ESTER IN CANINE ALLOGENEIC MARROW TRANSPLANTATION (1993) (11)
Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study (2003) (11)
New targets for therapy in acute myeloid leukemia. (2003) (11)
Long-Term Comparison of Immunosuppressive Therapy with Antithymocyte Globulin to Bone Marrow Transplantation in Aplastic Anemia (1990) (11)
Hematopoietic Cell Transplantation as a Form of Immunotherapy (2002) (11)
Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts. (1991) (11)
Infusion of a Non HLA-Matched Off-the-Shelf Ex Vivo Expanded Cord Blood Progenitor Cell Product Following Myeloablative Cord Blood Transplantation Is Safe, Decreases the Time to Hematopoietic Recovery, and Results in Excellent Overall Survival (2014) (11)
Haematological cancer: The rule of three in AML induction—is cladribine the answer? (2012) (11)
Hematopoietic Stem Cell Transplantation (2003) (10)
Indications for allogeneic hematopoietic cell transplantation for acute myeloid leukemia in the genomic era. (2014) (10)
131 I-Anti-CD45 Antibody Plus Busulfan/Cyclophosphamide in Matched Related Transplants for Acute Myeloid Leukemia in First Remission. (2004) (10)
Phase I study of recombinant human interleukin-1 beta (rhIL-1 beta) in patients with bone marrow failure. (1994) (10)
Low Albumin, High Ferritin, and Thrombocytopenia Before Transplant Predict Non-Relapse Mortality (NRM) Independent of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI). (2009) (10)
Transfusions shortly before HLA-matched marrow transplantation for leukemia are associated with a decrease in chronic graft-versus-host disease. (1991) (10)
Marrow transplantation for severe aplastic anemia: the Seattle experience. (1984) (10)
Phase I study of high-dose dimethylbusulfan followed by autologous bone marrow transplantation in patients with advanced malignancy. (1987) (10)
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. (2021) (10)
Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. (2016) (10)
Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease (2019) (10)
Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed? (2017) (10)
Indications for hematopoietic cell transplantation in acute leukemia. (2008) (10)
Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG (2015) (10)
PRELIMINARY RESULTS OF A PHASE II TRIAL OF IODINE-131-LABELED ANTI-CD20 (B1) ANTIBODY THERAPY WITH BONE MARROW RESCUE FOR PATIENTS WITH RELAPSED B CELL LYMPHOMAS (1994) (10)
Anti-T cell antibodies as part of the preparative regimen in hematopoietic cell transplantation--a debate. (2012) (10)
Recombinant granulocyte‐macrophage colony stimulating factor followed by immunosuppressive therapy for aplastic anaemia (1993) (10)
A proposed objective way to assess results of randomized prospective clinical trials with acute graft‐versus‐host disease as an outcome of interest (2001) (10)
Age and the nature of acute myeloid leukemia. (2004) (9)
Maintenance therapy after allogeneic hematopoietic cell transplantation for acute myeloid leukemia. (2019) (9)
Recurrence of aplastic anemia following cyclophosphamide and syngeneic bone marrow transplantation: evidence for two mechanisms of graft failure. (1985) (9)
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997 (2015) (9)
The proportion of CD34+CD38low or neg myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia (2013) (9)
Dose intensity and the toxicity and efficacy of allogeneic hematopoietic cell transplantation. (2005) (9)
Follow-up report on the outcome of patients relapsing after autologous marrow transplantation for malignant lymphoma. (1993) (9)
Failure of a single cycle of high dose cyclophosphamide followed by intensive myeloablative therapy and autologous stem cell transplantation to improve outcome in relapsed disease (1994) (9)
Allogeneic Transplantation for Chronic Myeloid Leukemia (2007) (9)
Immunobiologic therapies for myelodysplastic syndrome. (2004) (9)
Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials (2018) (9)
Dose Dependent Enhancement Of Neutrophil Recovery By Infusion Of Notch Ligand Ex Vivo Expanded Cord Blood Progenitors: Results Of a Multi-Center Phase I Trial (2013) (9)
Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia (2019) (9)
Acute myeloid leukemia. (2008) (9)
A Phase II Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥60 Years of Age with High-Risk Relapsed or Refractory B-Cell Lymphoma. (2005) (9)
Recommendations for Donor HLA Assessment and Matching for Allogeneic Stem Cell Transplantation : Consensus Opinion of the Blood and Marrow Transplant Clinical Trials Network ( BMT CTN ) (2014) (9)
Comprar Thomas' Hematopoietic Cell Transplantation, 4th Edition | Karl G. Blume | 9781405153485 | Wiley (2009) (8)
Radiolabeled antibody therapy of human B cell lymphomas. (1991) (8)
Effects of treatment regimens on post marrow transplant relapse. (1991) (8)
Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) following autologous marrow transplantation in man. (1988) (8)
Dose intensity of preparative regimens for acute myeloid leukemia - one-size-fits-all or tailor-made? (2010) (8)
Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic (2013) (8)
189 – The Acute Leukemias (2012) (8)
Flow cytometric demonstration of decrease in bone marrow leukemic blasts after ‘Day 14’ without further therapy in acute myeloid leukemia (2017) (8)
Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706 (2005) (8)
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. (2020) (8)
Mobilization Of Blasts and Leukemia Stem Cells by Anti-CXCR4 Antibody BMS-936564 (MDX 1338) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (2013) (8)
Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric Patients. (2015) (8)
Myelodysplasia and myeloproliferative disorders (1997) (8)
A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605) (2010) (8)
The role of hematopoietic cell transplantation as therapy for myelodysplasia. (2011) (8)
Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. (2017) (8)
Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid (2016) (8)
Use of recombinant human granulocyte macrophage colony-stimulating factor to speed engraftment and treat graft failure following marrow transplantation in man. (1990) (7)
Comparison of two intravenous cyclosporine infusion schedules in marrow transplant recipients. (1988) (7)
Sequential combination chemotherapy (containing high-dose cyclophosphamide) for metastic osteogenic sarcoma. (1978) (7)
Bone marrow transplantation for myelodysplasia in adults and children: when and who? (1998) (7)
Elevated expression of the AF 1 q gene , an MLL fusion partner , is an independent adverse prognostic factor in pediatric acute myeloid leukemia (2004) (7)
TREATMENT OF B‐CELL LYMPHOMA WITH I‐131 LABELED MURINE MONOCLONAL ANTIBODIES.: P10 (1987) (7)
Acute Myeloid Leukemia , Version 3 . 2019 (2019) (7)
Identical twin bone marrow transplantation for hairy cell leukemia. (1984) (7)
Hematopoietic cell transplantation beyond first remission (2002) (7)
Dose intensity and the toxicity and efficacy of allogeneic hematopoietic cell transplantation (2005) (7)
Marrow transplantation for malignant lymphoma. (1987) (7)
I-Anti-CD 45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome (1999) (7)
The influence of transfusions from unrelated DLA-matched or mismatched donors upon marrow grafts between DLA-identical canine littermates. (1988) (7)
Recipient-specific donor cytotoxic T lymphocytes enhance engraftment of unrelated, DLA non-identical canine marrow. (1994) (7)
International Working Group Scores Predict Post-Transplant Outcomes In Patients with Myelofibrosis (2010) (7)
Allogeneic marrow transplantation for acute non-lymphoblastic leukemia: first remission versus after first relapse. (1989) (7)
Hematopoietic cell transplantation beyond first remission. (2002) (7)
Microgranular Variant (M3V) of Acute Promyelocytic Leukemia (APL) Does Not Have a Worse Prognosis than Classical APL in the Atra Era: A Report of 153 Patients Treated on Intergroup 0129 and Pethema LPA96 and LPA99. (2004) (7)
Characterization of Malignant Lymphoma in Dogs and Use as a Model for the Development of Treatment Strategies (1988) (7)
Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia. (2021) (7)
Acute Myeloid Leukemia in Adults (2008) (7)
New targets for therapy in acute myeloid leukemia (2003) (7)
Fatal hepatotoxicity associated with AMSA therapy. (1982) (7)
Is there a better way to deliver total body irradiation? (1992) (7)
Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes:An analysis of four SWOG studies (2018) (7)
Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer: an economic analysis of a randomised, double-blind, placebo-controlled trial. (1994) (7)
Fatal hepatotoxicity associated with AMSA therapy. (1982) (7)
Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603) (2018) (6)
Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach (2020) (6)
Myeloablative radiolabeled antibody therapy with autologous bone marrow transplantation for relapsed B cell lymphomas. (1995) (6)
Use of trimetrexate for the prevention of graft-versus-host disease. (1989) (6)
Late Relapses Following All-Trans Retinoic Acid for Acute Promyelocytic Leukemia Are Uncommon, Respond Well to Salvage Therapy and Occur Independently of Prognostic Factors At Diagnosis: Long-Term Follow-up of North American Intergroup Study I0129 (2011) (6)
Decreased IRF8 expression found in aging hematopoietic progenitor/stem cells (2009) (6)
Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy (2015) (6)
Impact of residual normal metaphases in core binding factor acute myeloid leukemia (2012) (6)
Impact of Pre-Transplant Minimal Residual Disease Assessed by Flow Cytometry on Outcome Following Myeloablative Hematopoietic Cell Transplantation for Patients with AML-CR1. (2008) (6)
Reduced Relapse and Similar Progression-Free Survival After Double Umbilical Cord Blood Transplantation (DUCBT): Comparison of Outcomes Between Sibling, Unrelated Adult and Unrelated DUCB Hematopoietic Stem Cell (HSC) Donors. (2009) (6)
Oral Small Molecule Inhibitor of VLA-4 Overcomes Adhesion Mediated Chemotherapy Resistance of Acute Myeloid Leukemia (AML) Blasts in Vitro, without Impairment of Normal Blood Cell Recovery When Combined with Chemotherapy in Vivo (2008) (6)
Evaluation Of Which Patients Get a Second Course Of 3+7 On Cooperative Group Trials For Newly Diagnosed Acute Myeloid Leukemia: A Report From SWOG (2013) (6)
Evidence generation and reproducibility in cell and gene therapy research: A call to action (2021) (6)
Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians. (2016) (6)
High-Dose Radioimmunotherapy of B Cell Lymphomas1 (1989) (6)
Failure of anti-Ia monoclonal antibody to abrogate transfusion-induced sensitization and prevent marrow graft rejection in DLA-identical canine littermates. (1988) (6)
Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies (2011) (6)
Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia (2022) (6)
EFFECT OF GM-CSF ON CIRCULATING GRANULOCYTE-MONOCYTE PROGENITORS IN AUTOLOGOUS BONE MARROW TRANSPLANTATION (1989) (6)
Total-Body Irradiation in Bone Marrow Transplantation (1990) (6)
Introduction and overview of interferon alfa in myeloproliferative and hemangiomatous diseases. (1990) (6)
G-CSF Priming, Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or Refractory Acute Myeloid Leukemia (AML). (2009) (6)
Treatment-Related Mortality and Relapse Rate from Time of Initiation of Post-Remission Therapy for Patients Receiving Allogeneic Transplantation, Autologous Transplantation or Intensive Chemotherapy: A Report from the Eastern Cooperative Oncology Group (ECOG) (2008) (6)
High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer (2000) (6)
Conventional and Pretargeted Radioimmunotherapy Using an Anti-Murine CD45 Monoclonal Antibody in a Syngeneic, Disseminated Murine Leukemia Model. (2006) (5)
Hammering away at solid tumors. (1987) (5)
Survival after T-Cell Replete Haplo-Identical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor Transplant for Acute Myeloid Leukemia (2014) (5)
Validation of the predictive power of the hematopoietic cell transplantation-comorbidity index (HCT-CI) for non-relapse mortality (NRM) and survival after allogeneic HCT (2006) (5)
Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival (2016) (5)
The impact of obesity and disease on busulfan oral clearance in adults (1999) (5)
The impact of obesity and disease on busulfan oral clearance in adults (1999) (5)
Multivariate Analysis of Response and Survival After Treatment with Clofarabine, Cytarabine and G-CSF Priming (GCLAC) In Relapsed/Refractory Acute Myeloid Leukemia (AML): Comparison with Prior Experience Using Fludarabine and Cytarabine Combination Regimens. (2010) (5)
NCCN Acute Leukemia Practice Guidelines. The National Comprehensive Cancer Network. (1996) (5)
Is there a best transplant conditioning regimen for acute myeloid leukemia? (2000) (5)
The role of radioimmunotherapy in bone marrow transplantation (1996) (5)
Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia. (1992) (5)
Methods for assessment of graft-versus-host disease [5] (multiple letters) (1998) (5)
Impact of Comorbidities on Early and Late Mortalities After Allogeneic Hematopoietic Cell Transplantation (HCT) (2011) (5)
Supportive care of the marrow transplant recipient: the Seattle Experience. (1990) (5)
A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients (2012) (5)
Hematopoietic growth factors after allogeneic marrow transplantation in animal studies and clinical trials. (1994) (5)
The NCI common toxicity criteria and treatment-associated mortality in acute myeloid leukemia. (2013) (5)
Soluble TNF receptor fusion protein (TNFRrFc; Enbrel) in the treatment of patients with myelodysplastic syndrome (MDS) (2000) (5)
Consolidation chemotherapy prior to hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. (2016) (5)
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia (2008) (5)
Unrelated hematopoietic stem cell donors as research subjects (2011) (5)
Optimal Timing of Marrow Transplantation for Patients with Acute Nonlymphoblastic and Acute Lymphoblastic Leukemia (1988) (5)
Reprint of: Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. (2015) (5)
Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study. (2020) (5)
Cell Signaling-Based Classifier Predicts Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (2015) (5)
Radioimmunotherapy and Hematopoietic Cell Transplantation (2007) (4)
The biology of graft rejection in a canine model of marrow transplantation. (1987) (4)
Vincristine sulfate liposomes injection concentrates vincristine in tumor tissue and bone marrow of tumor-bearing mice (2007) (4)
recommendations from an international expert panel, on behalf of the Diagnosis and management of acute myeloid leukemia in adults: (2010) (4)
Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy. (2018) (4)
Sensitivity of newly transplanted marrow to further irradiation. (1988) (4)
Identifying older patients with acute myeloid leukemia who may be candidates for reduced-intensity hematopoietic cell transplantation. (2011) (4)
A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma (2011) (4)
Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome (2002) (4)
Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine. (2011) (4)
Hematopoietic cell transplantation for adults with acute myeloid leukemia with minimal residual disease. (2015) (4)
Effect of recombinant canine stem cell factor, a c-kit ligand, on hematopoietic recovery after DLA-identical littermate marrow transplants in dogs. (1997) (4)
Multi-Institutional Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes (2011) (4)
Decreased Relapse Rates without Excessive Transplant Related Mortality Following Cord Blood Transplantation (CBT): A Matched Cohort Analysis Comparing Myeloablative Cord, Matched Unrelated, and Mismatched Unrelated Donor Transplants. (2008) (4)
Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG (2020) (4)
Treatment of acute myelogenous leukemia in patients over 50 years of age with V‐TAD: A southwest oncology group study (1995) (4)
Marrow transplantation in the treatment of patients with lymphoma. (1989) (4)
Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts (2014) (4)
Protection of dogs from lethal consequences of endotoxemia with plasma or leukocyte transfusions. (1980) (4)
Genomic Subtypes of Nucleophosmin (NPM1) Mutations Are Associated with Clinical Outcome in AML - a COG and SWOG Intergroup Collaboration (2016) (4)
Effect of Peripheral Blood Stem Cell (PBSC) Graft Composition on Graft Versus Host Disease (GVHD) and Mortality After Allogeneic Transplantation (2010) (4)
Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to t (2019) (4)
Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997 (2010) (4)
Improved outcomes with allogeneic hematopoietic cell transplantation. (2012) (4)
Recombinant human stem cell factor stimulates increased numbers of peripheral blood and marrow CFU‐GM, BFU‐E, CFU‐MIX, HPP‐CFC and CD34 + cells in baboons (1992) (4)
Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center (2013) (4)
Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody (90Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS) (2018) (4)
Succinyl acetone plus methotrexate as graft-versus-host disease prophylaxis in DLA-haploidentical canine littermate marrow grafts. (1992) (4)
High-dose radioimmunotherapy of lymphomas. (1993) (4)
What role for 15-deoxyspergualin in enhancing engraftment of unrelated, histoincompatible canine marrow grafts and preventing graft-versus-host disease? (1993) (4)
Next-generation sequencing for measuring minimal residual disease in AML (2018) (4)
Prognostic significance of initial clinical and molecular genetic features of acute promyelocytic leukemia (APL): Results from the North American Intergroup Trial, C9710 (2007) (4)
Impact of the Novel 5-Group Cytogenetic Risk Classification of MDS on Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT) (2011) (4)
ALLOGENEIC BONE MARROW TRANSPLANTATION IN IRRADIATED ADULT RABBITS (1987) (4)
Efficacy and Safety Of Lower-Dose Glucocorticoids For Initial Treatment Of Acute Graft-Versus-Host Disease: A Randomized Controlled Trial (2013) (4)
Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid Cancer (1994) (4)
Long-term complications of bone marrow transplantation. (1989) (4)
Pre-and post-transplant quanti fi cation of measurable ( ‘ minimal ’ ) residual disease via multiparameter fl ow cytometry in adult acute myeloid leukemia (2016) (4)
The Role of Marrow Transplantation in the Treatment of Leukemia (1985) (4)
Marrow transplantation for patients with acute lymphoblastic leukemia: the Seattle experience. (1992) (3)
Predictors of relapse and overall survival in Philadelphia chromosome[ndash ]positive acute lymphoblastic leukemia after transplantation (2003) (3)
Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes (2011) (3)
Prognostic Significance Of NPM1 mutations In The Absence Of FLT3-ITD in Older Patients With AML: A SWOG Report (2013) (3)
Age and the nature of acute myeloid leukemia. (2004) (3)
A phase II trial evaluating the efficacy of high‐dose Radioiodinated Tositumomab (Anti‐CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high‐risk relapsed or refractory non‐hodgkin lymphoma (2020) (3)
Safety and tolerability of the combination of ATRA + arsenic trioxide (ATO) + gemtuzumab ozogamicin (GO) in high-risk acute promyelocytic leukemia (APL): Initial report of the SWOG/Alliance/ECOG S0535 trial. (2015) (3)
Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy (2018) (3)
Marrow transplantation for malignant plasma cell disorders (1989) (3)
SAMARIUM-153 EDTMP: TECHNICAL ASPECTS OF IMAGING AND TREATMENT (1989) (3)
Outcome Following Hematopoietic Cell Transplantation for Patients with AML-CR1: Comparison between Matched-Sibling and Unrelated Allografts. (2007) (3)
Hematopoietic growth factors in marrow transplantation and radiation injury. (1990) (3)
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial (2022) (3)
Allogeneic stem cell transplantation for the treatment of hematologic malignancies: current indications and challenges. (1997) (3)
304: Effect of Substituting Fludarabine and Thymoglobulin for Cyclophosphamide in Busulfan-based Conditioning Regimens on T-cell Chimerism and outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT) (2008) (3)
Failure to immortalise human AML cells using human recombinant GMCSF in vitro and in vivo. (1989) (3)
Does histologic grading of inflammation in bone marrow predict the response of aplastic anaemia patients to antithymocyte globulin therapy? (1987) (3)
Minimal Residual Disease Does Not Impact Risk of Relapse in Myeloablative Umbilical Cord Blood Transplant Recipients: Comparison with Matched and Mismatched Unrelated Transplants (2014) (3)
Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia (2015) (3)
E. Donnall Thomas (1920–2012) (2012) (3)
Higher Doses of Transplanted T and B Cells Are Associated with Greater Incidence of Extensive Chronic GVHD after PBSC Transplantation from HLA-Identical Sibling Donors. (2007) (3)
Decreased IRF 8 Expression in Aging Hematopoietic Progenitor / Stem Cells (2008) (3)
The Pitfalls of Early Publication of Data in Acute Myeloid Leukemia: A Report from the Eastern Cooperative Oncology Group (ECOG). (2008) (3)
Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia. (2021) (3)
Results of Allogeneic Marrow Transplantation in Patients Transplanted for Acute Leukemia: A Long-Term Follow-Up (1986) (3)
Long-term follow-up of 103 patients who received recombinant human granulocyte-macrophage colony-stimulating factor after unrelated donor bone marrow transplantation. (1993) (3)
Failure of recombinant stem cell factor to enhance engraftment of L-leucyl-L-leucine methyl ester treated canine marrow after irradiation. (1996) (3)
High Throughput Drug Screening of Leukemia Stem Cells Reveals Resistance to Standard Therapies and Sensitivity to Other Agents in Acute Myeloid Leukemia (2018) (3)
Biotherapy after marrow transplantation and the use of hematopoietic growth factors. (1990) (3)
Minimal Residual Disease Detection By Next Generation Sequencing in Adult B-Cell Acute Lymphoblastic Leukemia (ALL) Patients Treated on SWOG Trial S0333 (2014) (3)
Leukemia and related disorders (2012) (3)
The clinical spectrum of adult acute myeloid leukemia (AML) associated with core binding factor (CBF) translocations (2005) (3)
Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614) (2018) (3)
FAILURE OF ANTITHYMOCYTE SERUM POSTGRAFTING TO OVERCOME “RESISTANCE” TO DLANONIDENTICAL CANINE MARROW GRAFTS1 (1988) (3)
Hematopoietic effects and clinical uses of granulocyte-macrophage colony-stimulating factor and PIXY321. (1994) (3)
Impact of RLA matching and cyclosporine on long-term survival in transplanted rabbits. (1990) (3)
Pretargeted Radioimmunotherapy Using an Anti-CD45 Antibody-Streptavidin Conjugate and Radiolabeled DOTA-Biotin in Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (2013) (3)
Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia (2015) (3)
Pretargeted Radioimmunotherapy Using an Anti-CD45 Antibody-Streptavidin Conjugate and Radiolabeled DOTA-Biotin in Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (2013) (3)
Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM). (2007) (2)
Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia (2008) (2)
Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) Concentrates Vincristine in Tumor Tissue and Lymphoid Malignancy Oriented Tissues in Tumor-Bearing Mice. (2007) (2)
A Phase II Study Of Tosedostat (TST) In Combination With Either Cytarabine Or Decitabine In Newly Diagnosed Older Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (MDS) (2013) (2)
A Myeloablative Regimen Incorporating Radiolabeled Anti-CD45 (BC8) Antibody Followed by Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Advanced Acute Myeloid Leukemia (AML). (2004) (2)
AML in the Elderly: a Biologically Distinct Disease in which MDR1 Expression and Unfavorable Cytogenetics Contribute to Poor Clinical Response. Studies of the Southwest Oncology Group (1998) (2)
Acute Leukemias in Adults (2013) (2)
Bone Marrow Transplantation or Chemotherapy After Remission Induction for Adults with Acute Nonlymphoblastic Leukemia (2020) (2)
Hypomethylating agents as maintenance therapy following allogeneic hematopoietic cell transplantation for myeloid malignancies. (2021) (2)
Novel Dual E-Selectin-CXCR4 Inhibitors Mobilize Human Acute Myeloid Leukemia (AML) Cells in the NODscid IL2Rγc−/− Xenograft and Confer Susceptibility to Cytarabine (2011) (2)
Crossing the bridge from hematologic malignancies to solid tumors. (1986) (2)
A Phase I Study Of Myeloablative Radioimmunotherapy Using Iodine-131 Anti-CD45 Antibody Followed By Autologous Stem Cell Transplantation For High-Risk B-Cell and T-Cell Non-Hodgkin Lymphoma and Hodgkin Lymphoma (2013) (2)
Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML). (2010) (2)
Infusion of “off-the-shelf” Third Party Ex Vivo Expanded Cord Blood Progenitor Cells As Supportive Care Following Clofarabine with High Dose Cytarabine and Granulocyte Colony-Stimulating Factor Priming for the Treatment of AML, (2011) (2)
Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM). (2007) (2)
RADIOLABELED ANTIBODY THERAPY OF RELAPSED B CELL LYMPHOMAS (1993) (2)
Adhesion Receptor Expression by Acute Myeloid Leukemia (AML) Bone Marrow Derived or Circulating Blasts and AML Stem Cells: The Key to Overcoming Chemoresistance. (2009) (2)
Does histologic grading of inflammation in bone marrow predict the response of aplastic anaemia patients to antithymocyte globulin therapy (1987) (2)
Treatment of marrow donor blood products with gamma-irradiation prevents transfusion-induced sensitization to DLA-identical marrow grafts. (1991) (2)
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Is It Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? (2015) (2)
Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease (2019) (2)
Transfusion of autologous cytotoxic cells leads to failure of unrelated, DLA-nonidentical marrow grafts. (1990) (2)
A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance). (2017) (2)
Failure of anti-MHC antibodies to prevent GVHD in DLA mismatched unrelated canine marrow recipients. (1990) (2)
Outcome of Hematopoietic Cell Transplant from HLA-Matched Siblings Compared to a Volunteer Unrelated Donors Matched for HLA-A, B, C, DRB1, and DQB1 Alleles. (2007) (2)
Regimen‐intensity per count‐recovery and hospitalization index: A new tool to assign regimen intensity for AML (2020) (2)
Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study (2018) (2)
Blood consult: monosomal karyotype acute myeloid leukemia. (2012) (2)
Relationship Between Pre-Transplant Nutritional Status and Outcomes of Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. (2022) (2)
Impact Of Cytarabine Dose In The Induction Regimen On The Outcome Of Patients With Newly Diagnosed Acute Myeloid Leukemia With Or Without NPM1 and/Or FLT3 Mutations: A SWOG and MD Anderson Cancer Center Report (2013) (2)
Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710. (2006) (2)
Marrow grafting for acute leukemia: results and future treatment strategies. (1990) (2)
Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia (2020) (2)
Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18–60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG (2011) (2)
Interaction of Age and Comorbidities and Their Impacts on Hematopoietic Cell Transplantation (HCT) Outcomes (2011) (2)
Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia (2020) (2)
Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203 (2018) (2)
Indications for bone marrow transplantation (BMT) in the treatment of acute myeloid leukemia (AML). (1993) (2)
Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR (2021) (2)
Predictive facts and prevention of acute graft-versus-host disease (1988) (2)
Indications for bone marrow transplantation (BMT) in the treatment of acute myeloid leukemia (AML). (1993) (2)
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm AML patients. (2022) (2)
Improved Survival Following HLA-Matched Related Marrow Transplantation in Pediatric Patients with Severe Aplastic Anemia: (A 39-Year Retrospective Analysis) (2011) (2)
Intensive chemotherapy or chemoradiotherapy with autologous marrow support as treatment for patients with solid tumors. (1988) (2)
Transplantation of allogeneic peripheral blood stem cells. (1996) (2)
Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation (2022) (2)
Association between early promoter methylation changes and outcome in older acute myeloid leukemia patients treated on SWOG S0703 (NCT0065884). (2015) (1)
Cytarabine dose for acute myeloid leukemia. (2011) (1)
Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for AML in First Morphological Remission (2015) (1)
Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS (2017) (1)
Treatment of refractory acute leukemia with high-dose chemotherapy. (1977) (1)
Utility of Treatment-Related Mortality (TRM) Score to Predict Outcomes of Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation (2022) (1)
novel biologic clusters for risk classification and outcome prediction Gene expression profiling of adult acute myeloid leukemia identifies (2008) (1)
Marrow transplantation from HLA-identical siblings for treatment of aplastic anemia: is exposure to marrow donor blood products 24 hours before high-dose cyclophosphamide needed for successful engraftment? (1983) (1)
Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL). (2005) (1)
American Society for Blood and Marrow Transplantation guidelines for training. (2001) (1)
Characteristics and Prognostic Effects of DNMT3A Co-Mutations (2022) (1)
The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). (2019) (1)
Impact of Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry Pre and Post Transplantation, On Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (2012) (1)
To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decision. (2012) (1)
Clinical manifestation of chronic graft-versus-host disease (cGVHD) after transplantation of peripheral blood stem cell (PBSC) compared to bone MARROW (BM) (2000) (1)
Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets from ECOG and SWOG Trials (2012) (1)
Pre-transplant Neutropenia Is Associated with Poor Risk Cytogenetic Features and Increased Infection-related Mortality in Patients with Myelodysplastic Syndromes (2008) (1)
Prospective Phase II Multicenter Study of Conditioning with Treosulfan, Fludarabine and Low-Dose (2 Gy) Total Body Irradiation Followed by Hematopoietic Cell Transplantation From Related or Unrelated Donors for Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome (2012) (1)
Outcome and Prevalence of Hyperdiploidy and Hypodiploidy in Adults with Newly Diagnosed Acute Lymphocytic Leukemia: A SWOG Study (2011) (1)
Prevalence and Clinical Implications of IDH2 R140 and R172 Mutations in Older Adults with AML: A Report From SWOG, (2011) (1)
Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count (2019) (1)
Select high risk genetic features predict earlier progression following chemotherapy in chronic lymphocytic leukemia: Prospective randomized trial (Intergroup E2997) to evaluate justification for risk-adapted therapy. (2006) (1)
Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603) (2018) (1)
The Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact On Outcome in Acute Myeloid Leukemia (2012) (1)
Assessment Of The Value Of a Day 14 Bone Marrow In Newly Diagnosed AML (2013) (1)
Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia (2021) (1)
Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin (2021) (1)
9. Radiolabeled antibody therapy of lymphoma (1993) (1)
Allogeneic marrow transplantation for myelodysplastic syndrome (MDS) using unrelated donors (URD) (1994) (1)
Allogeneic Hematopoietic Cell Transplantation for AML: is it Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? (2015) (1)
Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia (2022) (1)
Relationship between CD33 Expression, P-Glycoprotein-Mediated Drug Efflux, and Clinical Outcome in Patients Treated in Phase II Trials with Gemtuzumab Ozogamicin Monotherapy. (2006) (1)
Anti-CD45 Ab Pretargeted Radioimmunotherapy Using An Alpha Emitting Radionuclide (213Bi) Delivers Selective Radiation to Human Myeloid Leukemias in a Mouse Xenograft Model and Results in High Rates of Complete Remission and Long Term Survival. (2009) (1)
Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia (2022) (1)
Measure for Measure: Measuring the Impact of Measuring Residual Disease in Acute Myeloid Leukemia. (2017) (1)
Allogeneic and Syngeneic Marrow Transplantation for Aplastic Anemia: Overview of Seattle (1988) (1)
Risk factors associated with increased grades III-IV acute graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) (2006) (1)
Treatment of Relapsed B Cell Lymphomas with High Dose Radioimmunotherapy and Bone Marrow Transplantation (2018) (1)
RELAPSE DOSE CHEMOTHERAPY OF BURKITT'S LYMPHOMA IN (1978) (1)
Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study. (2012) (1)
Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia (2016) (1)
Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival ("Potential Cure") over the Past Four Decades: Analysis of SWOG Trial Data (2017) (1)
Frequency of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission at an Academic Center (2012) (1)
Marrow Transplantation for Severe Aplastic Anemia (2020) (1)
Innovations in preparative regimens for autologous hematopoietic cell transplantation. (2005) (1)
All-Trans-Retinoic Acid Maintenance for Acute Promyelocytic Leukemia (2001) (1)
JAMA Peer Reviewers in 2019. (2020) (1)
Hematopoietic Stem Cell Transplantation: A Historical Perspective (2002) (1)
ncreasingly Frequent Diagnosis of Acute astrointestinal Graft-versus-Host Disease after llogeneic Hematopoietic Cell Transplantation (2004) (1)
Dedication - Dr. E. Donnall Thomas (2000) (1)
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. (2021) (1)
Chemotherapy: Lo and behold, a role for lomustine in acute myeloid leukemia? (2010) (1)
Early Discharge and Outpatient Management of Adult Patients Following Intensive Induction Chemotherapy for MDS and Non-APL AML: A Pilot Study (2010) (1)
Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium (2018) (1)
Immunosuppressive agents for prevention of graft-versus-host disease (1995) (1)
Frequent PML-RAR α Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710. (2006) (1)
Cyclosporine (CSP) or CSP plus methylprednisolone for graft-versus-host- disease prophylaxis in patients with high-risk lymphohemopoietic malignancies (2000) (1)
Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy (2011) (1)
Quantitative Significance of Minimal Residual Disease Before Myeloablative Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First and Second Complete Remission (2012) (1)
Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission (2019) (1)
VLA-4 Function and Prognosis in Acute Myeloid Leukemia (2015) (1)
Unrelated donor hematopoietic cell transplantation (HCT) as treatment for acute myeloid leukemia (AML) in first remission (2007) (1)
A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables. (2010) (1)
Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design (2014) (1)
RELATIONSHIP OF SERUM CYTOKINES (TNF-ALPHA, IL-1-BETA, IFN-GAMMA AND INFLAMMATION MARKERS (NEOPTERIN, BETA-2-MICROGLOBULIN, C-REACTIVE PROTEIN) TO TRANSPLANT-RELATED COMPLICATIONS AND IMMUNOGLOBULIN PROPHYLAXIS FOLLOWING ALLOGENEIC MARROW TRANSPLANTATION (1994) (1)
Impact of Pre-Transplant Comorbidities on the Rate of- and Mortality-Following Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation (HCT) (2011) (1)
Progress in adult acute lymphoblastic leukemia. (1996) (1)
Allogeneic Marrow Transplantation for Malignancy—Current Problems and Prospects for Improvement (1989) (1)
Prognostic Implications of the IDH1 synonymous SNP rs11554137 In Pediatric and Adult AML: a Children's Oncology Group and Southwest Oncology Group Study (2010) (1)
Influence of Residual Normal Metaphases In Patients with Monosomal Karyotype. (2010) (1)
Erratum: Decreased IRF8 expression found in aging hematopoietic progenitor/stem cells (Leukemia (2008) 10.1038/leu.2008.176) (2009) (1)
Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease after HLA-Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation (2016) (1)
Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning (2019) (1)
Who Participates in an Adult Cooperative Group Trial for Adolescent and Young Adults (AYAs)? Baseline Demographic and Psychosocial Characteristics of AYAs Enrolled On Intergroup Trial C10403 for Acute Lymphoblastic Leukemia (ALL) (2012) (1)
A phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia: SWOG S0703 protocol--Report on the good-risk patients. (2012) (1)
Allogeneic stem cell transplantation for the treatment of hematologic malignancies (1997) (1)
Bone marrow transplantation for leukaemia--current status and strategies for improvement. (2004) (1)
Relapse of Acute Leukemia After Marrow Transplantation (2016) (1)
Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Befor (2012) (1)
The Novel 5-Group Cytogenetic Risk Classification of Myelodysplastic Syndrome (MDS), Monosomal Karyotype, and Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT) (2012) (1)
The CXCR4 Inhibitor Plerixafor Effectively Mobilizes Primary AML in NODscid IL2Rγc−/− Xenografts and Markedly Reduces but Does Not Eradicate Leukemia in Combination with Cytarabine +/− Clofarabine Chemotherapy (2011) (1)
Over-Expression of Novel IRF8 Splice Variants Is Associated with a Significant Decrease In Relapse-Free Survival In Adult AML Patients. (2010) (1)
CD38 Status of CD34+ Myeloblasts, but Not Side Population (SP) Frequency, Predicts Initial Response to Induction Therapy In Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). (2010) (1)
An asterisk indicates reviewers who have evaluated three or more manuscripts in 2012. (2013) (0)
Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203 (2021) (0)
Atypical Myeloproliferative Disorder : Further Analysis of the ZNF 198 Gene and Lack of Evidence for Multiple Genes Disrupted on Chromosome 13 (1998) (0)
Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34) Defines a Very Poor Risk Leukemia Subgroup with Distinguishing Clinicopathological Features: A United States (US) Cytogenetics Intergroup Study of 62 AML and MDS Cases. (2004) (0)
Outcome of Acute Myeloid Leukemia Patients with Abnormal 12p after Allogeneic Hematopoietic Cell Transplantation at Fred Hutchinson Cancer Research Center (2017) (0)
Karyng about karyotyping in adult ALL (2007) (0)
Contributors (2012) (0)
Frequency of Allogeneic Stem Cell Transplant(SCT) in Patients Presenting with Newly-Diagnosed AML or AML at Time of First Salvage Therapy. (2009) (0)
18 NEW MEMBERS ELECTED BY SCIENCE ACADEMY (2014) (0)
SWOG S0919: A phase II study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML). (2013) (0)
Comparative trials of chemotherapy and bone marrow transplantation in acute nonlymphocytic leukemia. (1990) (0)
Preclinical and Clinical Studies of Hematopoietic Growth Factors in the Setting of Marrow Transplantation1 (1994) (0)
Blood consult Blood consult: monosomal karyotype acute myeloid leukemia (2012) (0)
FLT3,RAS, andTP53mutations in elderly patients with acute myeloid leukemia (2001) (0)
Long-term Outcome of Patients with Multiple Myeloma after Autologous Hematopoietic Cell Transplantation and Nonmyeloablative Allografting Running title: Auto-Allotransplant in Multiple Myeloma (2008) (0)
Treatment of patients with relapsed or refractory acute myelold leukemia (AML) with recombinant engineered human anti-CD33 antibody-calicheamicin drug conjugate (1997) (0)
Flow cytometry cannot assess surface binding of perforin to target cells (0)
Changes in the Pattern of Cytogenetic Aberrations with Advancing Age in Acute Myeloid (Non-APL) Leukemia: A Southwest Oncology Study (S9007). (2006) (0)
Frequency Of Allogeneic Stem Cell Transplant (SCT) In Patients Presenting With Newly-Diagnosed AML Or AML At Time Of First Salvage Therapy (2010) (0)
comparing cyclosporine plus prednisone versus prednisone alone Therapy for chronic graft-versus-host disease: a randomized trial (2013) (0)
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report (2020) (0)
Patient Donor Gender Patient female Donor female Donor multiparous Patient and donor negative Acute myeloid leukemia Non-Hodgkin ' s lymphoma Acute lymphoid leukemia Hodgkin ' s disease CML Multiple myeloma (2002) (0)
Allogeneic hematopoietic stem cell transplantation for myeloﬁbrosis (2003) (0)
Survival After Failure of Initial Therapy for Newly-Diagnosed or Relapsed/Refractory AML At An Academic Center: Subsequent Clinical Trial Vs. Not (2011) (0)
Hammering away at solid tumors. (1987) (0)
Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG (2014) (0)
Alteration Of Cytogenetic Risk Stratification In New Diagnosis Of Leukemia By FISH Testing – Retrospective Review Of The SWOG Experience (2013) (0)
A model for prediction of FLT3‐ITD and NPM1 (without FLT3‐ITD) positivity in patients with newly diagnosed acute myeloid leukaemia (2013) (0)
A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) (2012) (0)
PF256 RATIFY: PROGNOSTIC IMPACT OF FLT3 TYROSINE KINASE DOMAIN (TKD) AND NPM1 MUTATION STATUS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) TREATED WITH MIDOSTAURIN + STANDARD CHEMOTHERAPY (2019) (0)
Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia (2020) (0)
Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm (2012) (0)
DNMT3A Mutations Independently Predict Poor Outcome in Older AML Patients: A SWOG Report, (2011) (0)
Mechanisms of Cure of Acute Myeloid Leukemia with Allogeneic Transplantation (2000) (0)
Significance of Peri-Transplant Dynamics of Minimal Residual Disease (MRD) in Adults with Acute Myeloid Leukemia (AML) in Morphological Remission Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation (2015) (0)
Glutathione S-Transferase Theta 1 Gene Deletion and Risk of Acute Myeloid Leukemia 1 (2000) (0)
What pediatrics can teach us. (2011) (0)
Treatment-inﬂuenced associations of PML-RAR (cid:1) mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia (2012) (0)
CHIPs and engraftment dips. (2017) (0)
NUP98/NSD1 Translocation Further Risk-Stratifies Patients With FLT3/ITD In Acute Myeloid Leukemia: A Report From Children’s Oncology Group and SWOG (2013) (0)
disease following prior therapy or antecedent hematologic disorders syndrome: similar outcomes in patients with de novo disease and syndrome or acute myeloid leukemia arising from myelodysplastic Hematopoietic cell transplantation in patients with myelodysplastic (2013) (0)
Barriers to Successful Implementation of Precision Medicine to the Treatment of Refractory AML: Lessons Learned (2017) (0)
Thanks to Reviewers2004 (2004) (0)
The application of radioimmunotherapy to marrow transplantation (1995) (0)
Estimation of radiation dose to red marrow in myeloablative 131I-BC8 (anti-CD45) radioimmunotherapy for high-risk myelodysplastic syndrome and advanced AML: Sacrum vs acetabulum (2010) (0)
Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data (2022) (0)
Treatment of Acute Myeloid Leukemia Evolving from Myelodysplasia (2012) (0)
Chronic Phase of Chronic Myeloid Leukemia: Developed for the American Interferon, and Allogeneic Bone Marrow Transplantation in Treating the An Evidence-Based Analysis of the Effect of Busulfan, Hydroxyurea, (2013) (0)
BMT Tandem Meetings Best Abstracts (2018) (0)
Strickland, Eunice S. Wang, Kristina M. Gregory and Maoko Naganuma (2013) (0)
Supportive care of the marrow transplant recipient (1990) (0)
Association of Graft-Versus-Host Disease and Immunosuppressive Treatment with Risks of Recurrent Malignancy and Mortality After Allogeneic Hematopoietic Cell Transplantation (2010) (0)
Optimizing the conditioning regimen for acute myeloid leukemia (2011) (0)
Appelbaum consult : monosomal karyotype acute myeloid leukemia Blood (2012) (0)
hematopoietic cell transplantation cell responses following allogeneic + specific CD8 - Generation of HIV-1 (2011) (0)
Using a Transplant Recipient as a Donor: The Resilience of Multipotent Stem Cells in Humans (2017) (0)
chronic GVHD Evaluation of NIH consensus criteria for classification of late acute and (2009) (0)
Allogeneic stem cell transplantation for the treatment of hematologic malignancies: current indications and challenges. (1997) (0)
Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106 (2015) (0)
A Precision Medicine Approach Incorporating Both Molecular and In Vitro Functional Data to Treat Patients with Relapsed/Refractory Acute Myeloid Leukemia (2016) (0)
A Precision Medicine Approach Incorporating Both Molecular and In Vitro Functional Data to Treat Patients with Relapsed/Refractory Acute Myeloid Leukemia (2016) (0)
High Dose Radiolabeled Antibody Therapy of Lymphoma 1 (2006) (0)
Content Vol. 136, 2016 (2016) (0)
Acute Lymphoblastic Leukemia After Marrow Transplantation Transcripts in Philadelphia Chromosome-Positive (1997) (0)
HLA-identical marrow transplantation in the leukemias without T-cell depletion. The Seattle Marrow Transplant Team. (1990) (0)
Morphology Vs. Multiparameter Flow Cytometry in Evaluation of AML in Cerebrospinal Fluid (CSF). (2012) (0)
Treatment of refractory acute nonlymphocytic leukemia with a combination of pyrazofurin and cytarabine. (1982) (0)
Allogeneic Marrow Transplantation for Acute Nonlymphoblastic Leukemia in Adults (1985) (0)
Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report (2019) (0)
Tumor localization of radiolabeled antibodies to a human erythroleukemia zenograft in the nude mouse (1991) (0)
Lack of association between geographic factors and survival in hematopoietic cell transplantation. (2014) (0)
Treatment of refractory acute non-lymphocytic leukemia with pyrazofurin (PZF) and cytosine arabinosine (ARA-C) (1981) (0)
Oncology Group/Eastern Cooperative Oncology Group study postremission therapy in adult acute myeloid leukemia: a Southwest Karyotypic analysis predicts outcome of preremission and (2013) (0)
Efficacy a nd S afety o f G emtuzumab O zogamicin i n P atients With C D33-Positive A cute M yeloid L eukemia i n F irst Relapse (2001) (0)
Toxicity Trial ofProphylactic 9-(2-Hydroxy-1-(Hydroxymethyl)Ethoxymethyl)Guanine (1988) (0)
Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data (2011) (0)
386: Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Graft-versus-host Disease (GVHD) Prophylaxis after Hematopoietic Cell Transplantation from Unrelated Donors (2008) (0)
Novel Long-Term Co-Culture Approach Identifies Prognostically Important Heterogeneity Of Stem/Progenitor Cell Involvement In Human Acute Myeloid Leukemia (2013) (0)
prednisone does not compromise patient outcomes Initial therapy of acute graft-versus-host disease with low-dose (2009) (0)
bone marrow transplantation Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic (2011) (0)
98 – Acute Leukemias in Adults (2014) (0)
Lack of Utility of Chimerism Studies at Day 80 after Myeloablative Hematopoietic Cell Transplantation for Acute Lymphocytic Leukemia. (2006) (0)
Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study (2018) (0)
AML-145: Multicenter 11-Year Experience of Outcomes After Intensive Versus Less-Intensive Therapy for Patients with Acute Myeloid Leukemia: Focus on Older and Medically Infirm Patients (2020) (0)
Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms (2022) (0)
170: Long-Term Outcome of Nonmyeloalative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM) (2008) (0)
Bone marrow transplantation for acute nonlymphocytic leukemia (ANL). (1990) (0)
Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report (2016) (0)
Validation of a disposable, closed system for radiolabeling of monoclonal antibodies with high dose Iodine-131 (2007) (0)
2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials (2018) (0)
Comparative Effectiveness Analysis Of CD34+Selected, T-Cell Depleted (TCD) HLA-Matched Sibling Grafts On Allogeneic Hematopoietic Cell Transplantation For Patients With Acute Myeloid Leukemia (AML) In Complete Remission (2010) (0)
Targeted therapy for hematologic malignancies: has its promise been realized? Editorial review (1995) (0)
TRANSPLANTATION Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia (2015) (0)
Generation of HIV-1–speciﬁc CD8 (cid:1) cell responses following allogeneic hematopoietic cell transplantation (2008) (0)
Supplementary Material for: Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia (2016) (0)
Outcomes in the Recent Seattle Cord Blood Experience: Low TRM and Relapse; High Mild Acute GVHD and CMV Reactivation. (2007) (0)
Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM). (2009) (0)
Approaches to Improving the Results of Total Body Irradiation in Marrow Transplantation (2020) (0)
igration of Transfused Granulocytes in Leukopenic Dogs (2005) (0)
Effect of Allogeneic Hematopoietic Cell Transplant in First Complete Remission on Post-Relapse CR Rate and Survival in Acute Myeloid Leukemia (2014) (0)
Secondary Leukemia or Myelodysplasia Treated by Bone Marrow Transplantation (2001) (0)
Antibody in Normal Dogs : Dosimetry and Clinical Implications Effects of Propylthiouracil on the Biodistribution of an Iodine-131-Labeled Anti-Myeloid (2006) (0)
Prevalence of Chromosomally Integr 6 in Patients with Human Herpesvir ated Human Herpesvirus us 6 e Central Nervous System Dysfunction (2015) (0)
Global Proteomic Profiling Identifies Novel Prognostic Factors in Undifferentiated Leukemia Blasts from Patients with NPM1 Mutations: A Previously Unreported Approach to Biomarker Discovery from the Fred Hutch and SWOG (2021) (0)
prevention of acute graft-versus-host disease compared with a combination of methotrexate and cyclosporine for Marrow transplantation for severe aplastic anemia: methotrexate alone (2011) (0)
Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network. (2023) (0)
Alive in continuous remission Alive after relapse Transplant deaths ’ Causes of Death Relapse Graft failure and infection Without GVHD CMV pneumonia Other infection Hemorrhage VOD of liver CMV pneumonia Other infection Pulmonary failure With chronic GVHD Infection CMV pneumonia (2003) (0)
Marrow transplantation for patients with severe myelodysplasia. (1989) (0)
Autologous Bone Marrow Transplantation in Acute Leukemia (1985) (0)
Adult Cord Blood Transplantation (CBT) Vs. Unrelated Donor Transplantation: A Cost Comparison (2008) (0)
RNA-Sequencing Unveils Cryptic Fusions in Patients with Acute Myeloid Leukemia (2012) (0)
CCTG on the world stage at ASCO 2017 (2020) (0)
bone marrow transplantation for children with acute leukemia Phase I trial of interleukin-2 after unmodified HLA-matched sibling (2011) (0)
disease in patients undergoing marrow transplants? What role for prednisone in prevention of acute graft-versus-host (2011) (0)
A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma (2012) (0)
Increments in Acute Myeloid Leukemia Cells Cholesterol Synthesis and Import Contribute to Protective Cholesterol (2013) (0)
OP17 Arsenic trioxid improves survival in first line APL consolidation treatment: the NCI/CALGB study results (2007) (0)
Myeloablative Umbilical Cord Blood Transplantation for Hematologic Malignancies Is Comparable to Unrelated Donor Transplantation: A Retrospective Single-Center Study (2012) (0)
Clonal Markers In Relapsed Acute Promyelocytic Leukemia (APL): Clinicopathological Associations and Relation to All-Trans Retinoic Acid (ATRA) Treatment on Intergroup Phase III Trial C9710. (2010) (0)
NCCN Acute Myeloid Leukemia , Version 3 . 2017 Clinical Practice Guidelines in Oncology (2017) (0)
Reviewers for the Journal, July-December 2017. (2019) (0)
Gemtuzumab ozogamicin (2012) (0)
Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data (2019) (0)
Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report (2021) (0)
that engraft lethally irradiated baboons The ligand for c-kit, stem cell factor, stimulates the circulation of cells (2011) (0)
Conditioning regimens in bone marrow transplantation (1991) (0)
macrophage colony-stimulating factor Molecular cloning and in vivo evaluation of canine granulocyte (2003) (0)
Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm, (2011) (0)
T AIIogeneic Marrow Transplantation Randomized Study Comparing Corticosteroids and Cyclosporine (1985) (0)
Marrow grafting for acute leukemia (1990) (0)
Analysis of CRLF2/JAK Expression and Mutation Status In Adult ALL Patients (2010) (0)
Myeloablative radioimmunotherapy with I-131-BC8 (anti-CD45 antibody) for acute myeloid leukemia: Effect of spleen size and uptake on bone marrow absorbed dose (2007) (0)
Acute Lymphoblastic Leukemia After Marrow Transplantation Transcripts in Philadelphia Chromosome-Positive bcr-abl Detection of (2009) (0)
Automated Deep Aberration Detection from Chromosome Karyotype Images (2022) (0)
Expression of topoisomerase (topo) II in adult acute myeloid leukemia (AML): Relationships to immunophenotype and treatment outcomes. (2011) (0)
A Retrospective Comparison of Tacrolimus Vs. Cyclosporine for Immunosuppression After Allogeneic Hematopoietic Cell Transplantation with G-CSF-Mobilized Blood Cells (2010) (0)
Prognostic Methylation Markers for Survival in Cytogenetically Normal AML Patients Treated on SWOG Trials (2015) (0)
Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients. (2008) (0)
Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of “Acute Myeloid Leukemia, Not Otherwise Specified” in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center (2012) (0)
Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Speed of Neutrophil and Platelet Recovery (2011) (0)
Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients (2023) (0)
NCI Common Toxicity Criteria and Mortality After Chemotherapy for Acute Myeloid Leukemia (AML) (2012) (0)
Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data (2021) (0)
374: PUVA Therapy for Acute Graft-Versus-Host Disease (GVHD) of the Skin (2008) (0)
What Defines an 'Elderly Patient With AML'? (2006) (0)
male recipients of HLA matched related hematopoietic cell transplants Female donors contribute to a selective graft versus leukemia effect in (2013) (0)
Telomere Length Recovery Strongly Predicts Overall Survival in Acute Promyelocytic Leukemia (2014) (0)
Proof-Of-Concept Study For Precision Medicine With Chromosome Genomic Array Testing (CGAT) For Drug Sensitivity Screening In Acute Myeloid Leukemia (2013) (0)
irradiation in hematopoietic cell transplantation Prospective cohort study comparing intravenous busulfan to total body (2013) (0)
ozogamicin different resistance mechanisms to sensitize AML cells to gemtuzumab The peripheral benzodiazepine receptor ligand PK11195 overcomes (2013) (0)
[Long-term, complete remission in non-Hodgkin's lymphoma following high-dosage combination therapy with or without autologous bone marrow transplantation]. (1978) (0)
autografts for the treatment of patients with multiple myeloma Allografting with nonmyeloablative conditioning following cytoreductive (2013) (0)
KIT Mutations Are Rare Among Elderly AML Patients: A SWOG Report (2011) (0)
patients from intergroup protocol 0129 promyelocytic leukemia: assessment of prognostic significance in adult mRNA in acute α Quantitative real-time RT-PCR analysis of PML-RAR (2013) (0)
lymphoma: Cancer and Leukemia Group B study 19801 refractory T-lineage acute lymphoblastic leukemia or lymphoblastic Nelarabine induces complete remissions in adults with relapsed or (2013) (0)
Chromosome-Positive Acute Lymphoblastic Leukemia Marrow Transplants From Unrelated Donors for Treatment of Philadelphia (2011) (0)
Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia (2023) (0)
chronic myeloid leukemia The effects of imatinib mesylate treatment before allogeneic transplant for (2012) (0)
Thanks to Reviewers2000 (2000) (0)
Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission (2018) (0)
Reply to Z. Arlin "Bone marrow transplantation for chronic myelogenous leukemia: some thoughts about future prospects". (1988) (0)
Evidence-Based Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials (2016) (0)
allogeneic hematopoietic stem cells Conditioning with fludarabine and targeted busulfan for transplantation of (2013) (0)
131 I–anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in ﬁrst remission (2006) (0)
A Gentleman and a Scholar: Elihu H. Estey, MD (1946 –2021) (2021) (0)
Treosulfan, Fludarabine and 2 Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with MDS and AML (2014) (0)
Predictors of 90-Day Mortality after Admission to Intensive Care Unit (ICU) in Patients with Acute Myeloid Leukemia (AML): Application of a Novel, Recently Validated AML-Specific Risk Model (2018) (0)
Group study compared to cytarabine and daunorubicin: a Southwest Oncology myeloid leukemia is not improved with mitoxantrone and etoposide Outcome after induction chemotherapy for older patients with acute (2013) (0)
Preparative regimens in bone marrow transplantation: A panel discussion (1993) (0)
Metastatectomy followed by multi-agent intensive chemotherapy (CT) in osteosarcoma (1982) (0)
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study (2022) (0)
Antithymocyte Globulin Aplastic Anemia Conditioned by Cyclophosphamide Combined With Long-Term Follow-Up of Allogeneic Marrow Transplants in Patients With (2011) (0)
Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Platelet and Neutrophil Recovery. (2012) (0)
PF260 PROGNOSTIC AND PREDICTIVE IMPACT OF NPM1/FLT3-ITD GENOTYPES AS DEFINED BY 2017 EUROPEAN LEUKEMIANET RISK CATEGORIZATION FROM AML PATIENTS TREATED WITHIN THE INTERNATIONAL RATIFY STUDY (2019) (0)
Clinical and Functional Relevance of Interactions Between the Bone Marrow Stormal Microenvironment and Primary Human Acute Myeloid Leukemia (AML) Cells (2010) (0)
A Scoring System for Prediction of FLT3 -ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia. (2012) (0)
The Foregoing Letter was sent for Comment to Drs. Appelbaum and Deisseroth who Reply as Follows: (2009) (0)
T-Cell Acute Lymphoblastic Leukemia (2011) (0)
Very Late Antigen-4 (VLA-4) Expression by AML Blasts: Correlation of VCAM-1 Binding to Overall Survival. (2005) (0)
Acute lymphoblastic leukemia. (2002) (0)
Preface to the Fifth Edition (2005) (0)
factor in autologous marrow transplantation for lymphoid malignancies Use of recombinant human granulocyte-macrophage colony-stimulating (2011) (0)
A Phase II Trial of Radioimmunotherapy-Based Autologous Transplantation with I-131 Tositumomab, Cyclophosphamide and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (2015) (0)
Identification of Differential Methylation Markers Among Cytogenetic Risk Groups of Acute Myeloid Leukemia (2011) (0)
Inhibition of αvβ3 Integrin Disrupts Adhesion and Enhances Chemotherapy Effect in Multiple Myeloma Cells. (2007) (0)
Health consensus criteria and for chronic graft-versus-host disease according to National Comparative analysis of risk factors for acute graft-versus-host disease (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Frederick R. Appelbaum?

Frederick R. Appelbaum is affiliated with the following schools:

Frederick R. Appelbaum's Academic­Influence.com Rankings

Frederick R. Appelbaum's Degrees

Why Is Frederick R. Appelbaum Influential?

Frederick R. Appelbaum's Published Works

Published Works

What Schools Are Affiliated With Frederick R. Appelbaum?

Frederick R. Appelbaum's AcademicInfluence.com Rankings